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ABSTRACT 
The aim of this study was to develop a sensitive and specific method of detecting 
Toxoplasma gondii in the immunocompromised host which would reduce the need for 
other tests and would ensure the prompt initiation of the appropriate treatment, the 
effects of which could be monitored. Such a system would also be of benefit in the 
investigation of parasite / host interaction. 
Initial work investigated an antigen ELISA and the PCR using two different gene targets 
CB 1 and P30) to find the most sensitive system. The ELISA was insensitive but both 
PCR systems were capable of detecting parasite in blood, lymph and tissue samples from 
experimentally infected sheep. The B 1 PCR detected parasite earlier and over a 
significantly longer period than the P30 PCR, this greater sensitivity being due to the 
higher copy number of the B 1 gene. 
The PCR was applied to samples from patients with AIDS with the aim of finding an 
ideal sample for the diagnosis of infection. Parasite was detected in blood up to a month 
prior to clinical signs of infection, and therefore blood samples are ideal for monitoring 
patients at risk of recrudescence of a chronic infection. This result indicates that 
recrudescence is not due to local reactivation, but is due to a more widespread 
parasitaemia. However, as parasitaemia was shown to be transient in cases of 
recrudescence, sampling time may be critical. Parasite was also detected in urine, biopsy 
tissue and post mortem material, but was not detected in CSF. 
Dexamethasone was used to create a mouse model of recrudescence in the 
immunocompromised patient to further investigate interaction between the parasite and 
host. The PCR detected parasite in blood, brain and heart of chronically infected animals, 
however the detection rate was significantly higher in groups receIvmg 
immunosuppressive therapy. Dexamethasone treatment mimicked the effects seen in the 
AIDS population where 30-35% of chronically infected individuals showed clinical signs 
of toxoplasmosis. However the PCR may also be detecting latent cysts in tissue samples, 
and blood samples were occasionally positive without clinical evidence of infection. This 
could be due to small amounts of parasite circulating intermittently, or to breakdown 
products from parasite degradation. 
There was therefore a need to differentiate between active and chronic infection, and this 
was carried out by developing a quantitative PCR based on competitive amplification. A 
novel Sma I restriction site was created within the P30 gene, and known amounts were 
co-amplified with samples. The amplified products were then digested with Sma I to 
differentiate between mutated and T. gondii DNA and the point at which product yield 
was equalled indicated the amount of original DNA present in the sample. The system 
was shown to work using human PM samples, and could be adapted to indicate a cut-off 
point where parasite DNA levels reveal active infection. 
In conclusion the B 1 PCR is the method of choice in detecting T. gondii in AIDS 
patients. Any patient in which active parasite is detected should be treated and closely 
monitored using the qPCR for any evidence of reactivation. 
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CHAPTER 1 2 
1.1 BACKGROUND 
Interest in Toxoplasma gondii has increased greatly since its discovery in 1908 by 
Nicolle and Manceaux (cited by Fleck 1989b). The parasite's ability to infect a wide 
range of warm blooded animals has implications for both veterinary and human medicine. 
Infection in animals and humans is generally inapparent or mild, but infection during 
pregnancy can result in both high morbidity and mortality of the foetus. There are also 
serious implications for immunocompromised patients who have increased in numbers in 
recent years due to drug therapy, transplantation and the acquired immune deficiency 
syndrome (AIDS). It is this relatively new problem which has resulted in a substantial 
increase in research into the parasite and its complex lifecycle. 
1.2 TAXONOMY 
The name Toxoplasma gondii is derived from the appearance of the parasite and from 
the rodent Ctenodactylus gundi, from which it was first isolated. The genus name is from 
toxon, Greek for bow, and refers to the crescent shape of the tachyzoite. The full 
classification can be seen in Figure 1.1 as described by Wong and Remington (1993). 
Figure 1.1 Classification of T. gondii 
Phylum: Apicomplexa 
Class: Sporozoa 
Subclass: Coccidia 
Genus: Toxoplasma 
Species: gondii 
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1.3 HISTORY 
The parasite was first recorded at the beginning of the century and in 1923 cysts were 
found in the retina of an infant (described 'by Dutton 1989). In 1937 Wolf and Cowen 
reported cytoplasmic bodies in a case of megalencephaly, Sabin (1942) first suggested 
that these were obligate intracellular parasites, and demonstrated the importance of 
congenital infection and described signs of infection such as microcephaly, 
chorioretinitis, retinal calcification and convulsions. The connection between the 
consumption of undercooked pork and toxoplasmosis in humans was described by 
Weinman and Chandler in 1956, and cysts in meat from cattle, sheep and swine were first 
described by Jacobs et al. (1960b). However the discovery of the parasite in cat faeces 
by Hutchison (1965) was the key to discovering more about the complex lifecyc1e 
involved in the transmission of the disease. 
1.4 LIFECYCLE 
1.4.1 The Sexual Cycle 
The sexual cycle of T. gondii can only occur in the cat family which is the definitive host 
(Figure 1,2). Kittens usually become infected as they first start to hunt and consume 
meat containing tissue cysts. These cysts disrupt to release bradyzoites which 
differentiate into micro- and macro-gametes in the epithelial cells of the intestine. Fusion 
of these gametes results in the formation of a zygote which is surrounded by a protective 
wall and is known as the oocyst. These are shed in the faeces, and can be detected three 
days after ingestion of tissue cysts, with up to ten million being produced every day over 
a period of one to two weeks (Frenkel and Dubey 1972). Oocysts are not infectious until 
meiosis and sporulation occur between one and five days after shedding in the faeces. 
Oocysts containing eight sporozoites can remain viable in the soil for a period of months 
to years depending on conditions, with high moisture levels and a lack of frost increasing 
survival time (Ruiz et al. 1973). 
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Figure 1.2 The lifecycle of T gondii 
Sexual cycle 
1 
Ingestion by cat 
1 
Oocyst 
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penetration of gut wall 
Tachyzoite 
Proliferative form found in many cell types 
& in bloodstream early in infection 
4 
CHAPTER 1 5 
1.4.2 The Asexual Cycle 
When ingested by a susceptible intermediate host, the infectious sporozoites invade the 
cells of the digestive system and form tachyzoites, the proliferative form of the parasite. 
These are 1.5 /lm wide and between 3 and 4 /lm long (Fleck 1989a). The tachyzoites 
may be detected in the bloodstream early in infection, and invade most tissues of the 
body. The infection becomes latent in the tissue cyst form, which contains bradyzoites, 
and may persist for the life of the host. The lifecycle is maintained either by the ingestion 
of the tissue cysts by susceptible cats and the sexual cycle, or by the asexual cycle with 
ingestion of infected meat by an intermediate host. 
1.5 TRANSMISSION AND CELL INVASION 
Jacobs et al. (1960a) suggested that the consumption of raw or undercooked meat was 
responsible for transmission of T. gondii after the discovery that tissue cysts could 
survive the digestive process. In addition the group recognised that another route was 
indicated when strict vegetarians were also shown to have antibody and by 1970, 
infection through feline faecal contamination was seen to provide a further means of 
transmission (Sheffield and Melton 1970). Frenkel et al. (1970) provided support with 
the discovery that oocysts were capable of infecting mice after four months in soil. Oral 
infection with oocysts, either directly or via transport hosts such as flies is a means of 
transmission to the non-carnivorous host (Miller et al. 1972). Cat litter trays (Frenkel 
and Dubey 1972), and contaminated drinking water (Benenson et al. 1982) have been 
demonstrated to be sources of infection. Toxoplasma gondii in the human population can 
also be transmitted vertically to the foetus (Desmonts et al. 1985), and through medical 
procedures such as organ transplantation (Luft et al. 1983a), blood transfusion (Siegel 
et al. 1971) and accidental inoculation. These risks will be discussed further in section 
1.8. 
The observation that Toxoplasma can invade almost all cells, including non-phagocytic 
cells, stimulated a debate on the methods used by the parasite to enter host cells. Nichols 
and O'Connor (1981) found that cell invasion was more likely to occur by active 
penetration by the tachyzoite, whereas phagocytosis of the parasite occurred only rarely. 
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A study by Werk (1985) demonstrated that cell invasion by the tachyzoite occurs within 
15 to 40 seconds. In 1991 Achbarou et al. suggested that microneme proteins may 
contain receptors which are involved in parasite / host cell interaction, an area which 
deserved more investigation. Ossorio et al. (1992) found that ROPl, a rhoptry protein 
plays a part in host cell penetration. 
Immunity to the parasite is largely cell mediated although specific antibodies do have a 
role to play (Buxton 1993). Wilson and Remington (1979) found that phagocytes restrict 
rather than aid the initial dissemination of T. gondii. Interferon 'Y and other lymphokines 
are produced by sensitised T lymphocytes and an oxidative burst, produced by 
mononuclear phagocytes, kills the majority of organisms (Suzuki et al. 1991). Makioka 
and Kobayashi (1991) found that the recombinant P30 antigen (surface membrane 
protein of the tachyzoite) produced a fusion protein and was capable of activating 
macrophages to kill T. gondii in-vitro. As replication of the parasite becomes inhibited, 
cyst formation occurs in tissues throughout the host. 
A marked difference in susceptibility of inbred strains of mice to T. gondii was described 
by McLeod et al. (1989) who found that the degree of tissue infection after oral 
inoculation was controlled by at least five genes, primarily by the H-2 complex. This has 
raised the possibility that host genetic differences may contribute to the development and 
severity of the illness. Suzuki et al. (1991) found similar results in toxoplasma 
encephalitis after intra-peritoneal (i. p) inoculation of mice. 
1.6 MOLECULAR ANALYSIS 
T. gondii has been established as ancient from studies involving sequencing of the small 
subunit ribosomal RNA (srRNA) (Johnson and Baverstock 1989). This technique was 
used to provide information on the phylogenetic relationships of parasitic organisms 
based on the nucleotide divergence for 215 semi-conserved sites of the srRNA gene. The 
study revealed that the development of T. gondii is genetically closer to SarcocystiS than 
Plasmodium. 
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Little is known about the genetic background which regulates transition between the 
various forms of the parasite. However pulse field electrophoresis has revealed at least 
eight chromosomes (McLeod et at. 1991). The nucleus has been shown to be haploid 
during most stages of the lifecycle. However after the sexual cycle the diploid zygote is 
formed in the feline intestine as the unsporulated oocyst. The genome is estimated to 
consist of 8 x 107 base pairs (bp) with 53% (Neimark and Blaker 1967) or 55% 
(Cornelissen et al. 1984) guanine and cytosine content. 
The several genes which have been identified and sequenced include the P30 gene which 
encodes for the P30 surface protein (Burg et at. 1988), the Cl., and B tubulin genes 
(Nagel and Boothroyd 1988), and the P23 (Cesbron-Delauw et at. 1989), P28 (prince et 
at. 1989), and P22 (prince et al. 1990, Parmley et at. 1992a) genes. While these genes 
are known to have a clear purpose, others have also been investigated, including the B 1 
gene (Burg et al. 1989), but their functions are still unclear. Although the P30 gene 
contains 5 tandem repeats, only the B 1 gene is tandemly reiterated and contains between 
25 and 50 copies depending on the strain. This 2.2 kilobase (Kb) gene was singled out by 
McLeod et al. (1991) as a potential target for gene amplification for use as a diagnostic 
tool. 
1.7 ANIMALINFECTION 
Primary T. gondii infection in ewes during pregnancy results in significant losses to the 
sheep industry due to abortion or still birth (Buxton 1990, Dubey and Kirkbride 1989). It 
is also a significant problem in goats and pigs (Weinman and Chalmer 1956). Tissue 
cysts have been located in lamb (Dubey and Kirkbride 1989), pork (Dubey et al. 1986) 
and swine (Jacobs et al. 1960b). An accurate assessment of the scale of infection in farm 
animals cannot be made due to the prohibitive cost of screening large numbers for 
evidence of Toxoplasma IgG. Other factors such as the rapid loss of Toxoplasma 
antibody in cattle after infection make serological surveys of limited value in these 
animals. In the UK, toxoplasmosis is a problem in 10-20% of flocks. However the 
incidence of clinical toxoplasmosis in breeding ewes in Britain is estimated to be 2.2% 
per annum (Blewett and Trees 1987). The lack of a fully developed immune system 
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leaves the foetus poorly defended, and infection can lead to death particularly if it occurs 
early in gestation (Buxton and Finlayson 1986). Results from a study by Dubey and 
Kirkbride (1989) indicate that epizootics of Toxoplasma may occur in congenitally 
infected lambs. The most commonly recognised source of infection is contaminated 
pasture (Buxton 1990). 
Drugs such as monensin, an ionophorous antibiotic, have been used to reduce losses 
during lambing in experimental infections with T. gondii (Buxton et al. 1988). However, 
the production of a suitable vaccine would be more appropriate in the prevention of 
infection in sheep and other domestic animals. 
1.7.1 Vaccines 
Initial studies explored the possibility of passive infection using anti-tachyzoite serum or 
active immunisation with an experimental killed vaccine (Krahenbuhl et al. 1972) to 
induce protection against acute Toxoplasma infections. Partial protection was achieved 
with these methods. 
Later, purified antigens such as P22 and P30 were investigated. Kasper et al. (1985) 
found that these purified membrane proteins resulted in a high mortality rate in mice later 
challenged with parasite. However, Bulow and Boothroyd (1991) later found that 
immunisation with P30 in liposomes did successfully protect mice against challenge with 
T. gondii. Results revealed that only one out of 15 vaccinated mice died after subsequent 
exposure to the parasite compared with 11 out of 15 control mice. They suggested that 
the type of adjuvant and the route of administration were important in the success of the 
vaccine. Liposomes are a suitable adjuvant for use with P30 as they possess a 
hydrophobic lipid anchor, and they are also chemically stable. This study also found that 
P30 is highly conserved between strains and therefore appropriate for development into a 
subunit vaccine. 
Work has been carried out on a vaccine using live S48 tachyzoites to protect ewes 
(O'Connell et al. 1988, Wilkins et al. 1988, Buxton et al. 1991, Buxton 1993). 
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Vaccinated animals produced a higher number of viable lambs compared to 
non-vaccinated animals in experimentally infected pregnant ewes (72% compared to 
17.8% ). This strain has an incomplete lifecycle and so does not encyst. Therefore it 
poses little public health risk from the consumption of meat from inoculated animals. 
1.8 HUMAN INFECTION 
Toxoplasma gondii is one of the most common protozoan infections of man, affecting 
approximately 500 million people world wide (Hughes 1985). Levels of infection vary 
greatly from 80% in France, to 40 - 50% in the US (Wanke et al. 1987), and 20% in 
Scotland (Williams et al. 1981). The prevalence of infection would appear to be related 
to eating habits, climate and sanitary conditions. A higher incidence of antibody positive 
individuals was found in lower socio-economic groups and in those subjected to obvious 
risk factors such as the consumption of raw or undercooked meat, and exposure to an 
environment contaminated by feline faeces (Mills 1986). Toxoplasma does not transmit 
directly from one person to another, with the exception of congenital infection, where it 
can cross the placenta. 
1.8.1 Clinical Signs of Infection 
The vast majority of individuals infected with T. gondii suffer no serious clinical illness 
with the infection being self limiting and requiring no treatment (Krick and Remington 
1978). However infection can result in symptoms as varied as lymphadenopathy, 
myocarditis, encephalitis, brain lesions and blindness (Holliman 1988, Luft and Hather 
1990). There are three main groups of individuals who are at risk from serious disease 
which may even result in death: congenital infection when the mother contracts a primary 
infection during pregnancy (Desmonts et at. 1985); those immunosuppressed due to drug 
therapy for organ transplant or cancer therapy (Derouin et al. 1986); those with an 
immunological deficiency such as in AIDS (Luft and Remington 1988, Holliman 1991). 
Congenital infection 
Epidemiological studies indicate that the majority of T. gondii infections leading to 
ocular toxoplasmosis occur in utero (perkins 1973). Infants with congenital 
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toxoplasmosis are asymptomatic at birth or have non-specific symptoms such as 
jaundice, hepatosplenomegaly and intrauterine growth retardation. Infection in these 
individuals may only become apparent after up to 20 years (John son J. 1992), when 
sequelae such as retinochorditis occur. A minority do have severe manifestations 
including the Toxoplasma triad of hydrocephalus, intracranial calcification and 
retinochorditis (Hall 1992). Other complications can involve widespread tissue 
destruction of the central nervous system (CNS). Organs such as the liver, heart and 
lungs may also be affected. Maternal parasitaemia leads to congenital transmission in 
40-50% of foetuses (Joss et al. 1990), with infection during the first trimester causing 
most damage, although only 17% of cases are acquired during this period (Desmonts and 
Couvreur 1974). This is almost certainly due to the immature stage of the immune 
system and the greater effect of lesions on a small embryo, where several organs still in 
the early stage of development can be affected. As the foetus gets older so the immune 
system develops and offers more protection which may reduce the severity of infection 
(Ambroise-Thomas and Pelloux 1993). 
The scale of the problem in the UK remains unclear. Joss et al. (1990) and Ho-Yen 
(1990) estimate 2 out of 1000 pregnancies are affected to some degree with an estimated 
73 cases of congenital toxoplasmosis in Scotland each year. It was calculated from this 
that between 50 and 70 neonates will be seriously affected in England and Wales each 
year (Hall 1992). Fleck (1989a) reported estimates of a minimum of 130 asymptomatic 
cases a year, 30 with mild to severe symptoms and 15 resulting in neonatal death. At the 
highest estimate (Fleck 1989a) there may be 1,300 asymptomatic cases, 300 showing 
mild symptoms, 200 severe symptoms and 150 neonatal deaths per year. 
It is generally believed that only primary infection during pregnancy results in congenital 
infection. However some evidence challenges this belief (Holliman 1994), suggesting that 
the incidence of congenital toxoplasmosis from chronic maternal infection may occur 
with an incidence of 0-6%. The increase in mothers with human immunodeficiency virus 
(mY) infection and latent toxoplasmosis may therefore lead to recurrent parasitaemia 
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and to congenital infection although the mother may remain asymptomatic throughout 
the pregnancy (Holliman 1994). 
Management and prevention of infection during pregnancy has become an important 
issue which has been increasingly covered by the media. Health education remains the 
primary method of prevention, recommended by Jeannel et al. (1990) as vaccines are not 
yet available for use in women. In the UK there has been debate on the need for a 
screening programme for pregnant women, however this was rejected by a 
multi disciplinary working group on the grounds that there was a lack of evidence that 
benefits would outweigh the risks and costs involved (Hall 1992). The cost of the disease 
was estimated at £14 million by Beattie (1980) who was not convinced that universal 
surveillance and treatment would be cost effective. Others such as Ho-Yen (1990) 
recognise the benefits of a screening programme. This study estimated the cost of three 
tests throughout pregnancy to be between 0.7 and 1.2 times the preventable cost of 
providing care and support for affected children. Fleck (1989a) suggested a pilot study 
to determine whether such screening would be useful in the UK, and also that there 
should be more discussion between obstetricians, microbiologists and paediatricians to 
decide the best policy. 
Transplant Patients 
A study by Luft et al. (1983a) showed that a sub-population of patients who had 
undergone cardiac transplant, and who received immunosuppressive therapy to prevent 
rejection, developed serological changes consistent with T. gondii reactivation. Derouin 
et al. (1986) revealed that the clinical and serological manifestations of T. gondii are 
closely related to the recipients' serological status before transplantation. If the patient 
has evidence of past infection, immunosuppressive therapy may lead to secondary 
reactivation. This is generally asymptomatic, or in the form of a mild illness (Holliman 
1990). If a susceptible patient receives an organ from a donor with previous T. gondii 
infection there is a high risk of the development of serious or fatal toxoplasmosis 
(Wreghitt et al. 1989, Holliman et al. 1990a). As the parasite lies dormant in muscles, 
any organ from a donor with past infection may contain cysts. These could then 
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reactivate when the organ is introduced into a nruve recipient producing a primary 
infection (Speirs et al. 1988). Evidence of infection transmitted by a donor was found to 
be greater in cases of cardiac (57%), than in liver transplants (20%). No evidence of 
donor transmitted infection was found in renal transplants. This may be because 
Toxoplasma cysts are rarely if ever seen in the kidney (Speirs et al. 1988). 
AIDS Patients 
T gondii is one of the most common and treatable causes of CNS infection in AIDS 
patients. The incidence of toxoplasmosis in two AIDS surveys was shown to be 13.1 % in 
Spain (pedrol et al. 1990), and 3-10% in the USA (Luft et al. 1993). Luft and 
Remington (1988) reported that 95 % of toxoplasma encephalitis is due to recrudescence 
of a latent infection in these patients. This usually occurs when their CD4+ cell count 
drops below 100 mm-3 (Katlama 1991). This count is a marker of disease progression as 
the virus attacks T helper / inducer lymphocytes bearing the CD4 surface antigen. The 
defective cellular immune response interferes with the ability to mount an adequate 
response to intracellular organisms such as T gondii. In a study by Porter and Sande 
(1992) involving 115 patients with AIDS and CNS toxoplasmosis, the mean CD4+ cell 
count was 50 mm-3 . Vollmer et al. (1987) used a murine model in which T4 lymphocytes 
had been depleted and revealed an overwhelming systemic infection in acutely infected 
mice, with encephalitis in chronically infected mice. 
In the USA where 10-40% of those with mv have positive T gondii serology, one third 
of these IgG positive patients will develop toxoplasma encephalitis (Luft and Remington 
1992). Early estimates were lower at 6-12% (Wong et al. 1984). Grant et al. (1990) 
detected antibody to T gondii in 32% of patients, in which CNS toxoplasmosis 
developed in 24%, and estimated that 26% of patients were likely to suffer 
recrudescence within two years of the onset of AIDS. It is not clear why only 25-33% of 
patients with mv and latent T gondii infection develop toxoplasmosis. Host factors 
such as genetic disposition, observed by McLeod et al. (1989) and Suzuki et al. (1991), 
which was discussed in section 1.5 may account for this, but variation in virulence may 
also play a part. 
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In patients with chronic T. gondii infection who later develop AIDS the latent parasite 
can reactivate and invade many tissues. The parasite is believed to invade the CNS 
resulting in brain lesions and encephalitis. As the parasite can infect any cell in the brain, 
clinical symptoms of toxoplasma encephalitis are non-specific (Luft et al. 1993). 
Symptoms typically include seizures, headache and an altered mental state (Luft and 
Remington 1988). The development of infection in nervous tissue may be due to the lack 
of immunological control in the CNS (Ambroise-Thomas and Pelloux 1993). However 
the mechanism of parasite release from tissue cysts remains unclear and so the 
recognition of a system of local or systemic reactivation still requires investigation. Luft 
and Remington (1992) suggested that haematogenous spread of the organism may 
account for the multiple areas of the brain which are involved. Lymphadenopathy may 
be apparent, and other tissues such as the eyes are also affected resulting in 
chorioretinitis (Holland et al. 1988), and in severe cases the infection may become widely 
disseminated (Jacobs et al. 1991) for example causing pneumonitis. 
1.8.2 Diagnosis 
Direct methods of diagnosis of T. gondii infection employ the use of animal culture, cell 
culture, and histology. Sabin (1942) described the successful use of mice, guinea pigs 
and rabbits. However, although mouse inoculation (MI) is very sensitive, it is also very 
time consuming (Holliman 1988), taking up to six weeks to obtain a positive result. Cell 
culture can be carried out in monolayer cultures of human epithelial cells such as H.Ep-2 
cells (Bickford and Bumstein 1966), and also in MRC5 and Vero cells (Chimpitazi et al. 
1987). Parasite has been successfully isolated from cases of congenital toxoplasmosis 
using amniotic fluid (Derouin et al. 1988), and also from immunocompromised patients 
(Hofllin and Remington 1985, Calico et al. 1991, Tirard et al. 1991, Derouin et al. 1987 
and Dannemann et al. 1992). Histology is less time consuming than culture, but it is not 
so sensitive. Conventional staining techniques include haematoxylin-eosin (HE) and 
Wright-giemsa. Luft et al. (1984) found that these stains missed organisms in 50% of 
cases. The most effective immunohistochemical techniques include peroxidase-anti 
peroxidase (Conley and Jenkins 1981) and alkaline phosphatase which can detect free 
tachyzoites, tissue cysts and phagocytosed organisms. 
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The most common methods used in diagnosis of toxoplasmosis involve serology, and 
several commercial kits are available. The dye test (DT), developed by Sabin and 
Feldman in 1948 is still used by reference laboratories today. The test, based on a 
complement mediated neutralising antigen / antibody reaction requires live organisms and 
fresh complement, making it complicated and expensive. There are also risks associated 
with the use oflive parasite (Fleck 1989b). Methods such as the complement fixation test 
(CFT), enzyme-linked immunosorbent assay (ELISA) and direct agglutination test 
(DAT) are also used to detect IgG and IgM (McCabe and Remington 1983, Candolfi et 
al. 1987). Whole organisms are used in the DT, DAT and immunosorbent agglutination 
to detect antibodies to membrane antigens. These are most reactive early in infection. 
Other tests including CFT, ELISA, latex agglutination test (LAT) and indirect 
haemagglutination (IHA) use disrupted parasite. In the LAT, which is the most widely 
available commercial test, antigen is fixed to latex beads. Agglutination occurs when 
specific antibody is added and this test has good correlation with the DT (John son J. 
1992), although false positive results have been recorded (Holliman et al. 1989). Such 
tests do not generally detect infection as early as those using whole parasite, but they 
remain reactive for a longer period of time. This means that these tests would be of less 
value in prenatal screening regimes. The IHA test has shown cases of false negative 
results, and the end point of titration is often difficult to read (Fleck 1989a). The ELISA 
system was seen as the test of choice by Huglies (1985) as it requires little technical 
expertise, can be easily assessed, and is suitable for automation. Johnson J. (1992) 
reported satisfactory sensitivity when compared to DT, but variability in specificity and 
quantification capabilities. However the ELISA did not detect primary toxoplasmosis as 
early as the LA T, and is therefore better suited to the detection of previous exposure to 
infection (Sutehall and Wreghitt 1989). Joss et al. (1989a) found IgG ELISA's to be 
sensitive, detecting 86-91% of infected samples. Biotin-labelled T. gondii antigen was 
used with avidin labelled with peroxidase in an IgM capture ELISA (BAM-ELISA) by 
Joss et al. 1989b). This was found to be 100% sensitive and therefore useful for a 
screening test. IgA was found more frequently than IgM in cases of congenital 
toxoplasmosis by Decoster et al. (1991), and so they recommended the use of this test in 
combination with others to give a rapid diagnosis. 
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It has been suggested that strain variation may account for antibody diversity in patients 
(Weiss et al. 1988a) and studies involving the screening of new recombinant antigens for 
use in diagnostic serology have been carried out (Suzuki and Remington 1990, Parker et 
al. 1991 and van Gelder et al. 1993). Some of these have been aimed at the detection of 
different stages of infection, for example to detect only the tachyzoite (Decoster et al. 
1988, Suzuki et al. 1988a, 1988b and 1990). These involved the use of acute-stage 
specific antigens of T. gondii for serodiagnosis of acute infection. Results show that the 
system is sensitive and specific with 92% of sera obtained within two months of onset 
giving positive results, compared with 9% giving positive results after five months 
(Suzuki et al. 1990). 
Hassl and Aspock (1990) used immunofluorescent testing (IFAT) and western blotting 
to monitor IgG and IgM response in AIDS patients. Although sera recognised several 
bands, a pattern of antigens diagnostic of acute infection was not found. Potasman et al. 
(1986) reported that serum antibodies to certain antigens appeared to follow acute 
infection. They found an early antibody response to a 4 kDa antigen and 35 kDa antigen 
which may be of value in dot blot analysis. As many of the antigens are stage specific 
(Kasper 1989), they may be of value in the differentiation of stages of infection. 
Serological testing is useful in most patients. However it is of limited value in confirming 
congenital cases of toxoplasmosis, and in immunocompromised patients who have a 
limited ability to produce antibody. This is discussed further in section 1.9. There are 
very few tests available for the detection of T. gondii antigen, and none is commercially 
available (Wilson and McAuley 1991). Woodson and Smith (1990) reported that P30 
could not be detected in tissue cysts in samples of brain and that there is strain variation 
in cyst and bradyzoite antigens. This implies that P30 would be a suitable antigen to use 
in a detection system for tachyzoites and therefore an active or acute infection. 
The first antigen ELISA for detection of T. gondii was developed by van Knapen and 
Panggabean (1977), and since then several other systems have been published. These will 
be discussed in 1.9. 1. Their problem is that they appear to lack sensitivity (Wilson and 
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McAuley 1991) and as the duration of parasite in acute infection is brief, the diagnostic 
value remains to be proven (Barker and Holliman 1992). 
Dot-immunobinding analysis of antigens was capable of detecting 40-130 pg of antigen 
in mock samples, and also detected parasite in four out of six CSF samples from 
congenitally infected infants (Brooks et al. 1985). Others have used western blot analysis 
to characterise further antigens (Couvreur et al. 1988). Western blotting is a useful tool 
for determining antigens at different stages of infection, but is not easily transferred to a 
diagnostic setting (Wilson and McAuley 1991). 
Advances in DNA technology have resulted in new methods of diagnosis such as the 
detection of parasite nucleic acid by dot blot hybridisation (Angel et al. 1992, Blanco et 
al. 1992). These systems could not detect less than 1000 parasites in samples of infected 
tissue, blood, cerebrospinal fluid (CSF) and amniotic fluid. A probe developed from a 
genomic T. gondii library was found to be insensitive, with an ability to detect 3 ng of 
parasite (Savva 1989). 
1.8.3 Treatment 
A wide variety of drugs have been assessed for the ability to treat human toxoplasmosis. 
Spiramycin, a macrolide antibiotic is used to treat a primary infection during pregnancy 
because it can readily cross the placenta (Desmonts and Couvreur 1974). However its 
efficacy and safety have not been fully evaluated (Jeannel et al. 1990). 
Currently the drug of choice is pyrimethamine, a substituted phenyl pyrimidine 
compound, which can be used on its own at rates between 0.5 and 1 Ilg ml-1. However it 
is even more effective at lower levels when used in combination with sulphonamides, 
with which it has a synergistic effect (Harris et al. 1988). Pyrimethamine readily binds to 
protein, it is lipophylic, and it has a halflife of 35 to 175 hours before being cleared by 
hepatic metabolism. It operates by the inhibition of tetrahydrofolic acid formation by 
interfering with dihydrofolate reductase (Weiss et al. 1988b). These drugs are useful in 
treating congenital toxoplasmosis because they also readily cross the placenta (Hall 
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1992). Clindamycin and its analogues have also been used in combination with 
pyrimethamine and found to be effective treatments of toxoplasma encephalitis (Luft et 
al. 1993), although Jacobson et al. (1992) had to discontinue part of a trial assessing 
clindamycin treatment due to 40% of patients suffering side effects including diarrhoea 
and rash. 
If diagnosed early, patients usually respond rapidly to pyrimethamine / sulphonamide 
therapy. Using sulfadiazine (1 - 2 g 4x day) and pyrimethamine (25 - 50 ng Ix day), 
Wanke et al. (1987) found clinical improvement in 11 out of 13 mv positive patients 
with toxoplasma encephalitis, and a reduction in brain lesions in 8 out of 10 patients. 
Improvement was noted over the first 2 to 4 weeks, but recrudescence occurred 14 to 
42 days after stopping therapy. This reveals the problems which arise when treatment is 
suspended in the immunocompromised host. By blocking folic acid metabolism, only the 
tachyzoite is affected, and so the bradyzoites inside tissue cysts remain untreated and are 
able to reactivate when treatment is stopped or reduced. Treatment was stopped in 6 
out of 13 patients due to toxic effects including neutropenia, fever and rash (Wanke et 
al. 1987). Leport et al. (1989) found that toxicity was less of a problem in a study using 
pyrimethamine with clindamycin where only one out of 11 patients was affected. As 
pyrimethamine is toxic to bone marrow, supplemental therapy with folic acid is 
necessary. Other treatments such as rehydration and dose reduction may also be 
necessary (Weiss et al. 1988b, Luft and Remington 1992). 
As problems with relapse in immunocompromised patients are significant, maintenance 
therapy is routinely given after clinical improvement. This consists of continued lower 
daily doses of sulphadiazine and pyrimethamine, or pyrimethamine on its own. Pedrol et 
al. (1990) reported an incidence of 50% relapse in patients not receiving maintenance 
therapy, however in the study carried out by Wanke et al. (1987) relapse occurred in 
only 16.6% of patients receiving maintenance therapy. The use of intermittent 
maintenance therapy is therefore thought to be desirable, even if some relapse does 
occur. Similar results were obtained by Porter and Sande (1992) with 22% relapsing 
with, and 60% of patients relapsing without maintenance therapy. 
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The high levels of toxicity associated with these drugs highlights the need for less toxic 
agents in the treatment of toxoplasmosis. The need for drugs affecting the bradyzoites in 
tissue cysts was recognised by Huskinson-Mark et al. (1991) and Luft and Remington 
(1992). This would allow only one course of therapy and end the need for life long 
treatment and so reduce the problems associated with toxicity. They tested azithromycin, 
aprinocid-N-oxide and the hydroxynaphthoquinone 566C80 for effects on the bradyzoite 
in vitro with some success. The definitive action of 566C80 is unknown but it appears to 
target the mitochondrial respiratory chain, blocking electron transport. From the 
subsequent success of these drugs in in-vivo animal models it was concluded that further 
study in patients was warranted. The success of 566C80 in the treatment of 
Pneumocystis carinii in rats and mice as well as T. gondii infection would be of value as 
both infections are frequently encountered in patients with AIDS (Mills 1986). 
Vaccination has had a limited role in the prevention of T. gondii infection, and so far it 
has been limited to veterinary use (1. 7.1). For vaccines to be used successfully in the 
human population several problems need to be overcome. Firstly there is a need to find a 
vaccine which does not consist of live parasite, for example in the form of a protective 
recombinant antigen. This could then be manufactured in a suitable vector. Salmonella 
was suggested as a vector by Bulow and Boothroyd (1991) but the public distrust 
associated with this organism may prevent its use for human vaccine production. 
Secondly, there is a need to identify a susceptible population, as it would not be possible 
to control the massive animal reservoir of infection. As a result, humans not vaccinated 
would still be at risk. 
1.9 DIAGNOSIS IN HIGH RISK GROUPS 
Accurate and rapid diagnosis of infection in pregnancy (Holliman et al. 1991a) and in 
AIDS patients is essential for patient management and improved prognosis (Blanco et al. 
1992, Luft et al. 1983b). Antibody testing is of little value in cases of reactivation in 
imrnunocompromised patients if there is an absence of specific immunoglobulin (Mills 
1986, Wanke et al. 1987), and T. gondii antigenaemia and parasitaemia are rarely 
detected. Dannemann et al. (1991) followed 33 patients for between one and 14 
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months, and failed to detect parasite using MI and antigen ELISA, even in samples from 
two patients within 45 days of developing toxoplasma encephalitis. The importance of 
the detection of antigenaemia and parasitaemia remains unclear (Vendrell et al. 1993). 
As a result of this, diagnosis in these patients is often made on the basis of clinical 
findings, including the use of computer axial tomography (CAT) and magnetic resonance 
imaging (MRI). These scans can reveal brain lesions (Navia et al. 1986), but are far from 
conclusive as similar effects can be due to mv itself or to infection by other organisms 
such as Cytomegalovirus (CMV), Herpes simplex, Mycobacterium spp, Cryptococcus 
spp, Candida albicans and Aspergillis jumigatis (Luft and Remington 1988, Wanke et 
al. 1987). Therefore an important part of a diagnosis is to exclude other pathogens. 
Confirmation by pathological examination of a brain biopsy is an invasive technique, and 
is not considered acceptable in most situations (Barker and Holliman 1992). However it 
is considered to be necessary by Wanke et al. (1987) who rejected non-invasive 
techniques as not being sufficiently sensitive, particularly for patients who do not 
respond to therapy (Holliman et al. 1991 b) 
Management and prevention are therefore important in the control of the illness. IgG 
status is of value in locating patients at risk from reactivation of toxoplasmosis and mv 
positive patients with negative T. gondii serology should be given advice on avoiding 
primary infection. Patients who have been exposed to the parasite should be monitored 
for any neurological changes, especially in cases of advanced AIDS, (Luft and 
Remington 1992). As identification of those at risk minimises delay in diagnosis and 
therefore permits early therapy, routine screening using MRI and CAT scans and blood 
samples should be implemented (Grant et al. 1990), particularly if abnormal clinical signs 
are encountered in the CNS. Lumbar puncture and screening for IgG and IgM in the 
CSF collected should also be carried out in conjunction with testing for other organisms 
(Mills 1986). Although CSF may appear normal, Potasman et al. (1988) recognised the 
diagnostic value of testing for intrathecal antibody. If a diagnosis cannot be made, an 
aggressive regime is warranted, including brain biopsy and empiric therapy (W ong et al. 
1984). MRI and CAT scans are both useful in the assessment of response to therapy, 
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when evidence of improvement should be seen within three weeks if toxoplasmosis is the 
cause (Luft and Remington 1992). 
It is apparent that more sensitive methods of direct testing involving non-InVaSIVe 
procedures are necessary. The failure to detect parasitaemia and antigenaemia may be 
due either to the limitations of the tests used, or because the parasite is circulating 
intermittently (Dannemann et al. 1991), or transiently (Barker and Holliman 1992). The 
development of a more sensitive antigen detection ELISA and tests using DNA 
technology have been suggested for use with samples such as blood and urine. These 
would be much easier to obtain than biopsy specimens, cause less trauma to the patient, 
and could be collected sequentially, especially from patients being treated. 
The antigen ELISA has been developed over a number of years for the detection of T. 
gondii in samples from a wide variety of animals. Success rates varied greatly and so the 
standardisation of such a test would be necessary for its use in successfully diagnosing 
cases of toxoplasmosis where others have failed (van Knapen and Panggabean 1977, 
Araujo and Remington 1980, Lindenschmidt 1985). 
The polymerase chain reaction (PCR) was developed by Mullis in 1983, but not 
published until 1985 by Saiki et al. due to patent applications. This powerful method has 
been applied to the detection of small amounts of specific nucleic acid from a wide 
variety of organisms. These include CMV (Shibata et al. 1988), Pneumocystis carinii 
(Lipschik et al. 1992) and Papillomavirus (Morris et al. 1988). It is also capable of 
detecting genetic disorders and is used as a research tool and in forensic science (Kitchin 
1990). 
Amplification of specific nucleic acid occurs through a series of cycles of heating and 
cooling carried out in a programmable heating block. Double stranded DNA is first 
denatured by heating to a high temperature. Both strands can serve as a template for 
synthesis of DNA, therefore specific primers are added which flank the area to be 
amplified. When the temperature is reduced these primers anneal to the complementary 
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Figure 1.3 The Polymerase chain reaction. 
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part of the appropriate strand and are then used as the starting point for the creation of 
new strands of DNA. This requires the presence of building blocks of deoxynucleoside 
triphosphates (dNTP's) and DNA polymerase, which catalyses the reaction. The 
polymerase used is a thermostable Taq DNA polymerase is obtained from Thermus 
aquaticus, which maintains its efficiency over many cycles of temperature variation. 
After 25-30 cycles the amount of target DNA will have increased exponentially and can 
be detected by dot-blotting or electrophoresis (see Figure 1.3) (Kitchin 1990). 
1.9.1 Antigen ELISA 
Van Knapen and Panggabean (1977) carried out a study to investigate the use of an 
ELISA system to detect antigen. This involved 1 116 sera from individuals suspected of 
having toxoplasmosis, from which antigen was detected in 64 (5.7%). As circulating 
antigen (cag) was detected in so few patients suspected of having toxoplasmosis, it was 
suggested that antigen circulates for only a short period. Thus they reported that cag 
could only be found in the short active phase of primary infection and during reactivation 
and concluded that when carried out with antibody testing, antigen ELISA could provide 
valuable information on the present stage of infection. If antibody levels were high 
(IF AT> 1 024), and cag was detected, then they suggested that the cause of illness was a 
primary infection, and if antibody was low (IFAT<512, CF and IgM negative) with 
detectable cag, then the infection was considered to be in the latent stage. They also 
emphasised the advantage of obtaining a positive result with the antigen ELISA on the 
basis of one sample, in contrast to the requirement for paired sera when testing for 
antibody. 
A similar antigen detection ELISA was also used successfully by Araujo and Remington 
(1980) to test serum samples from 22 patients diagnosed as having acute toxoplasmosis. 
In this case purified F(ab)2 fragment ofIgG raised from Toxoplasma infected rabbits was 
used to coat the plate resulting in a detection rate of 63.6% (14 out of 22 patients). 
Araujo and Remington (1980) concluded that parasitaemia may only be present 
intermittently as 36.4% of cases of diagnosed acute toxoplasmosis failed to produce a 
positive result using this technique. 
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By 1985 interest in a system to detect T. gondii antigen had increased with the rising 
number of AIDS patients suffering from toxoplasmosis. As antibody testing is of limited 
value in immunocompromised patients an alternative system of diagnosis was required in 
these individuals. 
Lindenschmidt (1985) studied 51 patients with lymphadenopathy and found that 42 were 
T. gondii IgM positive. Out of these 42 patients, 30% were antigen positive by ELISA. 
This system used 3 M NaSCN to disassociate antigen / antibody immune complexes 
which were recognised as a problem in detection systems (Neurath et al. 1982). High 
levels of circulating antibody may bind antigen in serum thus making it unavailable for 
detection in the ELISA system. Using the system of van Knapen and Panggabean (1977) 
only 14.3% of samples were positive. Therefore Lindenschmidt (1985) concluded that, 
contrary to earlier finding, immune complexes may cause problems resulting in reduced 
sensitivity. 
Further work by van Knapen, Panggabean and Leusden (1985) used ELISA to 
investigate circulating immune complexes (CIC) in mice which had been experimentally 
infected with T. gondii. CIC were found by day 3 post infection (p.i.) with the RH strain. 
Using the non-virulent T626, strain which is probably more relevant to human infection, 
cag was detected for a very short period. This supported the hypothesis that free 
antigens only circulate for a limited period before CIC are formed. CIC were found from 
day 13 p.i. up to day 35. By day 75 the only evidence of past infection was antibody. 
Therefore in the mouse model the presence of CIC appears to parallel the acute and 
sub-acute stages of infection. 
The study by van Knapen et al. (1985) also compared serum from patients with 
suspected toxoplasmosis, and serum from patients with confirmed toxoplasmosis, and 
from a control group of blood donors. CIC was detected in 12.5% of patients with 
suspected toxoplasmosis, 37.5% of those with confirmed toxoplasmosis, and also in 
several of the control group. The number detected in the control group may have been 
due to a high level of infection in the population of The Netherlands where this study 
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was carried out. The final part of this study involved following a case infection resulting 
from a laboratory accident. In this case the level of cag was too low to be considered 
positive by ELISA. The individual had high levels of IgG and IgM, so the low amount of 
cag was explained by the formation of CIC, which was detected at initial infection and 
also at a later stage of infection. Van Knapen et at. (1985) noted that CIC represents the 
presence of active parasitaemia or acute toxoplasmosis and concluded that the detection 
of CIC may be indicative of active infection. However, as they are often detected in 
cases of asymptomatic infection, the test is of limited diagnostic value. 
A more refined ELISA using avidin-biotin (ABELISA) was developed by Ise et at. 
(1985). This was assessed as a possible method of detecting cag by using it to monitor 
experimentally infected rabbits. This system did not involve a dissociation step and could 
detect 4 ng ml-1 which compared well with the 30-50 ng ml-1 detection rate obtained by 
Araujo and Remington (1980). Improved detection was due to the high degree of affinity 
of avidin for biotin which is 106 times that of the affinity of antibody for antigen (Subba 
Reo et al. 1983). The system detected the RH strain 3 days post infection, after which it 
rose sharply until day 8-9 when all rabbits were dead. Using the Beverley strain, antibody 
levels increased with time, but all samples were antigen negative until the end of the 
study when all animals were still alive. Therefore the system missed what was concluded 
to be low levels of infection of the non-virulent strain. 
Transplant patients showing signs of T. gondii reactivation were studied by Candolfi et 
at. (1987). Antigen was detected in 14 out of 115 sera tested from 19 patients (12.2%). 
They found antigen in sera from patients with acute toxoplasmosis, whereas sera from 
chronically infected patients were negative, and they concluded that the presence of cag 
was associated with an active infection. Antigen was detected in the blood of 7 patients 
prior to the detection of symptoms, but antigenaemia appeared to be limited or at a very 
low level and they concluded that it was confined to patients suffering a reactivation of 
infection. 
r 
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Samples of serum and CSF from mv positive patients were tested for antigen by Hassl 
et al. (1988). They used the purified IgG F(ab)2 fragment to coat the ELISA plate in a 
similar method to Araujo and Remington (1980) and detected cag in 16% of patients, 
most of whom had progressed to the advanced stage of AIDS (stage iv). Symptoms of 
toxoplasmosis were found in only 13 of these patients and only 2 had detectable IgM. No 
cag was found in CSF, even with a toxoplasma encephalitis was present. The significance 
of detectable antigen in patients with AIDS was questioned by Hassl et al. (1988), who 
disagree with Araujo and Remington (1980) and van Knapen and Panggabean (1977) in 
their description of antigenaemia as being indicative of acute infection. 
Antigen was detected in the sera and urine from acutely infected mice using ELISA and 
western blot by Huskinson, Stepick-Biek and Remington (1989). All these studies have 
demonstrated several methods of using ELISA to detect antigen, including possible ways 
to increase sensitivity, but have not proven useful for the diagnosis of Toxoplasma 
encephalitis (Luft and Remington 1988). To this end it has been suggested that the use of 
monoclonal antibodies against secreted / excreted antigens may be useful for the 
detection of cag in human samples. An antigen ELISA was developed for use with sheep 
samples by Maley (1991), but had limited sensitivity and a level of300 ng of antigen had 
to be present before a positive result was recorded. Part of the aim of the following 
investigation is to explore the possibility of increasing the sensitivity of the antigen 
ELISA for the detection of T. gondii in human samples. 
1.9.2 Polymerase Chain Reaction 
Several systems have been described which use the PCR for the specific amplification of 
T. gondii DNA to levels detectable by gel electrophoresis. peR was first investigated by 
Burg et al. (1989) for use in the diagnosis of toxoplasmosis with the B 1 gene (see 1. 6) as 
the target. Quantitative Southern Blot analysis revealed that between 25 and 50 copies of 
this gene are present in the different strains of T. gondii, making it an ideal choice for 
amplification studies. Grover et al. (1990) found the gene to be present in all examined 
strains of the parasite (twenty one) demonstrating that it is highly conserved. Using 
purified T. gondii DNA, the system was found to be sensitive enough to detect a single 
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parasite after hybridisation with a labelled probe. The system was highly specific and did 
not amplify DNA from Sarcocystis, Neospora, Plasmodium, Aspergillis, Candida, 
Cryptococcus or Absidia spp .. However the system lost some sensitivity when used on 
mock clinical samples. In these samples, ten parasites could be detected in the presence 
of 104 leukocytes but it was concluded that the system needed further optimisation to 
increase sensitivity for clinical samples. Initial studies by Burg et at. (1989) used only 
one amplification of 25-60 cycles to give a 193 or 150 base pair (bp) product. The 
system has since been developed using nested amplifications (Lebech et at. 1992, 
Ho-Yen et at. 1992 and Verhofstede et at. 1993) to increase sensitivity. 
Several studies have been carried out to investigate the possible use of the B 1 PCR in the 
diagnosis of toxoplasmosis. These have involved the use of mock samples containing 
known amounts of DNA (Joss et al. 1993), and animal samples (Hitt and Filice 1992) 
The latter study compared B 1 PCR to MI and cell culture. Mouse inoculation detected 
parasite in 62% of samples compared to 37% by B 1 PCR and 25% by cell culture. 
The B 1 PCR has also been used to detect T. gondii from human samples. In 1990 
Verhofstede et al. reported its use to diagnose congenital toxoplasmosis in an infant 
using a CSF sample collected 10 days after birth. This was not confirmed by serological 
testing until 15 months later. Grover et al. (1990) investigated amniotic fluid from 43 
cases of acute maternal infection. B 1 PCR was positive in eight out of ten samples, 
whereas Toxoplasma IgM was detected in three samples, and tissue culture was positive 
in four samples. They highlighted the need for better methods of sample preparation as 
cell debris was shown to inhibit PCR. In the two samples negative by B 1 PCR, large 
numbers of red blood cells (RBC's) were present. They concluded that use of the PCR in 
cases of acute infection in pregnancy could reduce the number of unnecessary 
terminations presently carried out. The B 1 PCR was used to detect toxoplasmosis in 
three congenitally infected children, and also in post mortem (PM) tissues by van de Yen 
et al. (1991). Microscopy, tissue culture and MI were also investigated. The PCR gave 
results compatible with MI, only failing to detect parasite in one sample positive by MI. 
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However, Weiss et al. (1992) found that the B1 PCR often failed to detect T. gondii in 
tissue samples which had been stored frozen. 
Lebech et al. (1992) and Parmley et al. (1992b) studied CSF from 13 and 14 patients 
respectively using the B1 PCR. Lebech et al. (1992) detected parasite in two patients 
and Parmley et al. (1992b) detected Toxoplasma in four patients. No Toxoplasma DNA 
was detected in control samples. 
Parasite was detected in blood samples from three out of seven cases of reactivated 
infection where serology proved inadequate (Ho-Yen et al. 1992). However infection 
was not detected in 13 patients with ongoing toxoplasma lymphadenopathies. PCR 
results were supported by MI, and this further suggests that only a transient parasitaemia 
is present in acute infection in healthy individuals. 
The B 1 PCR was used to detect Toxoplasma DNA in aqueous humour in three cases of 
ocular toxoplasmosis (Brezin et al. 1991). The B1 gene target has also been used by 
GroB et al. (1992) to amplify a larger fragment using different primers. Of 52 tissue and 
amniotic fluid samples collected from five patients ten samples were shown to contain 
Toxoplasma DNA by the B1 PCR. All but one of these was confirmed by MI. 
The other DNA target which has attracted much attention is the gene coding for the P30 
surface protein (Burg et al. 1988). This system was developed by Sawa et al. (1990) 
using six different isolates from mouse culture to detect 0.5 pg of DNA after 
amplification, followed by gel electrophoresis and hybridisation studies. This was 
improved to detect 0.05 pg after a further amplification using nested primers. However, 
when mock samples were used, a smear of artefact bands often made the 522 bp product 
difficult to interpret when viewed on a gel. This was resolved by southern blotting and 
hybridisation. The system was also specific for T. gondii when tested against 
Hammondia hammondii, Cryptosporidium parvum, Giardia lamblia and Eimeria 
vermiformis. 
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The P30 PCR has been used to detect T. gondii in equine eyes, (Turner and Savva 1991) 
and in ovine tissue samples (Turner et al. 1991). Human samples have also been used 
successfully (Savva and Holliman 1990). These include brain biopsies from AIDS 
patients (Holliman et al. 1990b, Holliman et al. 1991 b) 
The P30 PCR was used to detect infection in cardiac transplant patients by Holliman et 
al. (1992). In a comparison between this technique and histology of cardiac biopsies 
from transplant patients, the PCR detected Toxoplasma DNA in eight samples whereas 
histology only detected Toxoplasma in two cases. Blood samples from AIDS patients 
were investigated by Dupouy-Camet et al. (1993) and in six out of seven proven cases of 
toxoplasmosis the P30 PCR gave a positive result, and 13 out of 14 samples from cases 
of presumptive toxoplasma encephalitis were also positive. Out of those followed up 
after treatment, several were still positive after 17 days of therapy. None of the 17 
control cases were shown to be positive. They concluded that the P30 PCR was a 
suitable tool for the diagnosis of cerebral and disseminated toxoplasmosis and that it may 
also be useful for monitoring the effects of treatment. Johnson et al. (1993) reported that 
the P30 PCR was more sensitive than cell culture and MI in samples from pregnant 
women, foetuses, neonates, AIDS patients and transplant patients. The P30 PCR was 
also employed by Dupouy-Camet et al. (1990) using different primers to create a 282 bp 
fragment and this was used successfully to detect parasite in samples from cases of 
suspected congenital infection. However several confirmed cases were negative with the 
test. This was explained by the P30 target gene containing only one copy which could be 
missed in samples containing very small numbers of parasite. 
Studies comparing different PCR methods have been limited. Both the Bland P30 PCR 
were used to investigate ocular samples from two patients by Brezin et al. (1990). B 1 
PCR detected parasite, but P30 PCR did not. A larger study was carried out by 
Verhofstede et al. (1993) on 33 CSF samples including nine from confirmed cases of 
toxoplasma encephalitis. The B 1 PCR was positive in six out of nine samples whereas 
the P30 PCR only detected two positive samples. They suggested that the higher copy 
number of the BI gene may account for the greater sensitivity of this test. 
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Other PCR systems have also been attempted. Ribosomal DNA (rDNA) was used as a 
target for amplification by Cazenave et al. (1991), to produce an 88 bp fragment over 35 
cycles, and Guay et al. (1993) amplified DNA from one parasite using rRNA as a target. 
A system for amplifying complimentary DNA (cDNA) was developed by Weiss et at. 
(1991), but this was found to be less sensitive than either the B 1 or P30 PCR methods 
(Verhofstede et at. 1993). 
1.10 AIMS 
The aim of the following study was to develop a sensitive method of detecting T. gondii 
in the immunocompromised host. Such a method would be of great diagnostic value and 
ideally would utilise samples obtained using non-invasive procedures. Specific diagnosis 
would reduce the need for further investigations and would ensure the prompt initiation 
of appropriate treatment. Two PCR systems and an antigen ELISA were investigated for 
this purpose, and to monitor the effects of therapy. A successful system would ensure 
that treatment was specific and appropriate and so minimise the risk of toxicity due to 
high doses of therapeutic agents. Such a system would also be of benefit in the 
investigation of parasite / host interaction with particular emphasis on the mechanisms 
involved in recrudescence. 
CHAPTER 2 
Preliminary Investigations: 
The use of the PCR and Antigen ELISA to detect T. gondii Infection 
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2.1 INTRODUCTION 
This initial investigation involved the development of the ELISA for the detection of T. 
gondii antigen and the PCR to detect T. gondii DNA. In the latter, methods using the Bl 
and P30 genes were developed as reports indicated that both are useful in the detection 
of T. gondii DNA from purified parasite and in infected human and animal samples 
(Holliman et at. 1991b, Turner et at. 1991). However these studies lacked adequate 
controls, and neither had been assessed for a role in diagnosis. While the PCR technique 
is relatively expensive and requires specialised laboratory facilities, various ELISA 
systems are already in widespread use throughout the world for the diagnosis of a range 
of organisms. An antigen ELISA would therefore be of value for the diagnosis of 
toxoplasmosis as it would be easy to implement in most diagnostic laboratories. 
2.2 MATERIALS AND METHODS FOR THE PCR 
2.2.1 Frequently used solutions 
Unless otherwise stated reagents were obtained from Sigma. Suppliers are listed In 
appendix I. 
PBS: 137 mM NaCl, 26.8 mM KCI, 8.1 mM N~HP04' l.47 mM 
~P04' 
TE: 
Phenol: 
Chloroform: 
10 mM Tris (pH 7.5), 0.1 mM EDT A, unless stated otherwise. 
Equilibrated with 1 M Tris-HCI (pH 8), then with 0.1 M Tris 
HCI (pH 8). B-hydroxyquinoline was added to 0.1 % (w/v) and 
stored at -20°C. 
Chloroform was mixed with isoamyl alcohol at a ratio of24:1 
(v/v) and stored in a dark bottle at room temperature. 
Phenol/Chloroform: Phenol and chloroform were mixed 1: 1 and stored at 4°C. 
Proteinase K: 
RNase A: 
20x SSC: 
5x Loening "E": 
Stock was made up at 20 mg ml-\ aliquoted and stored at -20°C. 
Stock was made up at 10 mg ml-1, heated to 100°C for 15 
minutes, cooled to room temperature and stored at -20°C. 
3 M NaCI, 0.3 M sodium citrate, stock solution adjusted to pH7 
with concentrated NaOH. 
900 mM Tris, 750 mM Na ~P04' 25 mM EDTA, pH7.6-7.8. 
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2.2.2 Parasite Preparation 
Parasite was passaged in Swiss White nuce every three days by intraperitoneal 
inoculation with 106 RH strain tachyzoites. Peritoneal exudate was removed and the 
parasite cleaned by washing with PBS followed by Hanks Balanced Salt Solution 
(Gibco) and then centrifuged at 500 g for 5 minutes. Parasites were counted using a 
haemocytometer and preparations containing a 98% tachyzoite suspension were used. 
(Work carried out by J. Wastling). 
2.2.3 DNA Extraction from T. gondii 
DNA was extracted from 109 T. gondii tachyzoites for use in developing the PCR and 
for future positive control material. Parasite was lysed in 50 mM Tris (pH 8.0), 50 mM 
EDT A, 1 % SDS, containing 100 Ilg ml-I proteinase K. After incubation at 50°C for three 
hours, the nucleic acid was extracted with an equal volume of phenol/chloroform 
followed by an equal volume of chloroform. DNA was then precipitated with 2 volumes 
of ethanol (100%) and 0.1 volume of 3 M sodium acetate at -20°C for 1 hour, followed 
by centrifugation at 10 000 g. The pellet was washed in 70% ethanol and then 
resuspended in TE. RNA was removed by incubation with 20 Ilg ml- I RNase for 30 
minutes at 37°C and the DNA was re-extracted and precipitated as above. 
2.2.4 DNA Extraction from CMV 
(Supplied by S. Burns, City Hospital). This method was adapted from those ofBrytting 
et al (1991) and Sandin et al. (1991). Aliquots of virus were frozen and thawed three 
times, digested using pronase (100 Ilg ml- I ), followed by phenol/chloroform and 
chloroform extraction. DNA was precipitated with ethanol (see 2.2.3) and the pellet was 
resuspended in 100 III TE. 
2.2.5 DNA Extraction from Candida albicans 
(Supplied by S. Burns,· City Hospital). This method was adapted from Monod et al. 
(1990). Cells were harvested and washed with 50 mM EDTA (pH 8), followed by 
centrifugation at 600 g. The pellet was resuspended in 150 III of 50 mM EDTA and 80 
III lyticase solution (2 ng lyticase in 10 mM Na P04 (pH 8), 50% (v/v) glycerol) and 
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incubated at 37°C for 20 minutes. Proteinase K (1 mg rnI-') was added in NDS buffer 
(0.5 M EDTA, 10 mM Tris pH 7.5, 1% (w/v) sodium laurylsarcocinate) and the digest 
was incubated at 50°C for 24 hours. DNA was extracted using phenol/chloroform, 
followed by chloroform extraction and precipitated with ethanol as before. The pellet 
was redisolved in TE and treated with RNase (20 Ilg rnI-') and re-extracted (see 2.2.3). 
The final pellet was redisolved in 100 III TE. 
2.2.6 DNA Extraction from Sarcocystis spp. and Pneumocystis carinii 
(Sarcocystis supplied by N. Lally, Moredun Research Institute; Pneumocystis carinii 
supplied by S. Burns, City Hospital). This was carried out as for T. gondii extraction. 
2.2.7 DNA Extraction from Aspergillis fumigatus 
(Supplied by S. Burns, City Hospital). This was carried out using the method of 
Denning et al. (1990). Cells were centrifuged at 1200 g and washed with 10 rnl of 0.6 M 
Mg S04' The pellet was resuspended in 3 rnl buffer (1.2 M Mg S04 buffered with 10 
mM K P04 to pH 5.8). This buffer was also used to prepare stock solutions of cellulase 
and Novozyme 234 at concentrations of 20 mg rnI-'. Equal proportions of each enzyme, 
0.5 rnl g-' wet weight of pellet were added, and cell wall digestion was carried out by 
shaking at 33°C for 60 - 90 minutes. The suspension was overlaid with separation buffer 
A (0.6 M sorbitol, 100 mM Tris (pH 7) ) and centrifuged at 1 500 g for 1.5 minutes. The 
protoplast layer was then removed from the interface and resuspended in 5 rnl 
separation buffer B (1.2 M sorbitol, 10 mM Tris, 50 mM EDTA (pH 7.5)), and 
centrifuged at 800 g for 10 minutes. Finally, the supernatant was removed and the pellet 
was washed twice and then resuspended in 5 rnl buffer B. 
DNA was then extracted by adding 0.5 rnIlysis buffer (2% (w/v) SDS, 50 mM EDTA 
pH 7.8). After mixing and incubating at 70°C for 30 minutes, the preparation was 
centrifuged at 8 000 g for 5 minutes. The pellet was then digested with 100 III proteinase 
K (100 Ilg rnI-' in distilled water) at 50°C for 1 hour. This was followed by phenol / 
chloroform extraction and ethanol precipitation (see 2.2.3). 
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2.2.8 Quantification of DNA 
The concentration of DNA preparations was assessed by taking readings of OD260 using 
a spectrophotometer (OD260 equal to 1 corresponds to 50 Ilg ml-I double stranded DNA). 
Readings were also taken at OD280 . DNA preparations free from protein possessed an 
OD260 : OD280 ratio approaching 2.0. 
2.2.9 Basic Reaction Conditions 
The PCR was carried out in a Techni PHC3 (Scotlab) thermal cycler over 30 cycles in 50 
III volumes which were overlaid with 50 III of mineral oil. Both PCR systems employed 
the use of nested primers. Primers were obtained from Oswell DNA Services, dNTP's 
from Pharmacia, and Taq DNA Polymerase from Boehringer Mannheim. Samples were 
initially denatured for 10 minutes at 95°C before the first amplification cycle to ensure 
that any DNA present was fully denatured. 
2.2.10 The P30 PCR 
The method of Savva et al. (1990) was used to amplifY the gene coding for the T gondii 
P30 surface protein. To optimise this system fully, titrations were carried out using 
varying concentrations of MgC~, KCI2, dNTP's and primers. The final conditions used 
over the rest of the study were in fact very similar to those of Savva, and were as 
follows: The reaction mixture consisted of 10 mM Tris (pH 8.3), 50 mM KCI, 1.5 mM 
MgCI, 0.1% (w/v) gelatin, 0.2 mM dNTP's, 0.2 IlM each primer and 2.5 units of Taq 
DNA polymerase. The primers used in the system were as outlined in Figures 2.1 and 
2.2. The first amplification was carried out using primers DS29 and DS30 to produce a 
fragment of 914 bp, followed by a nested amplification using primers DS38 and DS39. 
The fragment produced from the second amplification was 522 bp long. The cycle 
regime was as follows: denaturation at 95°C for 1 minute, annealing at 60°C for 1 
minute, and extension at 72°C for 3 minutes. 
2.2.11 The Bl PCR 
The method of Burg et al. (1989) was modified to amplifY the multi-copy B 1 gene. 
Titration of the components of the system revealed critical concentrations of MgCI and 
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Figure 2.1 Primers for the P30 peR 
DS29. TTGCCGCGC CCACAC TGA TG 
DS38. CGA CAG CCG CGG TCA TTC TC 
DS39. GCA ACC AGT CAG CGT CGT CC 
DS30. cGC GAC ACA AGC TGC GAT AG 
Figure 2.2 Positions of the primers on the P30 gene 
D829 0838 
5' 1 405-4241 503-524 3' 
I ClS29±Clsao 91~b~ 
0829+0839 620bp 
0838+0830 815bp 
0838+0839 522bp 
3' 
1005-1024 11299-13181 5' 
0839 0830 
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Figure 2.3 Primers for the B 1 peR 
PI. GGA ACT GCA TCC GTT CAT GAG 
P2. TGC ATA GGT TGC AGT CAC TC 
P3. GGC GAC CAA TCT GCG AAT ACA CC 
P4. TCT TTA AAG CGT TCG TGG 
Figure 2.4 Positions of the primers on the BI gene 
P1 P2 
5' I 694-714 I 757-776 3' 
P1+P3 159b~ 
P1+P4 193bp 
P2+P3 96bp 
P2+P4 130bp 
3' 831-853 I 868-887 5' 
P3 P4 
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KCI were necessary to fully optimise the reaction. The final conditions of the system 
were therefore quite different from those used by Burg, and were as follows: 10 mM Tris 
(pH 8.3), 2.5 mM MgCI, 40 mM KCI, 0.01% gelatin, 0.2 mM dNTP's, 0.2 IlM of 
each primer and 2.5 units of Taq DNA polymerase. Various primer combinations were 
used (see Figures 2.3 and 2.4) with P2 being used without the T7 site and containing 
only 20 bases. In the initial reaction PI and P4 amplified a 193 bp product. When this 
was followed by a nested amplification using P2 and P3, the product obtained was only 
96 bp. The cycle regime consisted of denaturation at 95°C for 1 minute, annealing at 
50°C for 1 minute and extension at 72°C for 3 minutes. 
2.2.12 Polyacrylamide Gel Electrophoresis 
Polyacrylamide gel electrophoresis (pAGE) of DNA was based on the method of 
Sambrook et al. (1989). Acrylamide stock (29.2% (w/v) acrylamide, 0.8% (w/v) 
bisacrylamide) diluted with Loening "E" buffer was used to make 7.5% polyacrylamide 
gels. The reaction was catalysed by 0.1% (v/v) N,N,N',N',-tetramethylethylenediamine 
(TEMED), and 0.1% (w/v) ammonium persulphate (APS) (Biorad), and the gels were 
poured immediately after their addition. Gels were cast using the "mini protean" gel 
system (Biorad) and run at 150 volts constant setting. 
2.2.13 Silver Staining of Polyacrylamide Gels 
DNA in polyacrylamide gels was stained using a modification of the method of Herring 
et al. (1982). Gentle agitation was used for all the steps of the staining procedure. The 
gel was first fixed in 100 rnl of 10% (v/v) ethanol and 0.5% (v/v) ethanoic acid for 10 
minutes, followed by staining in 11.2 mM AgN03 for 10 minutes. After washing twice in 
distilled water the bands were developed by the addition of 0.75 M NaOH containing 
0.25% (v/v) formaldehyde for a further 10 minutes. The reaction was stopped when the 
bands became clearly visible by removing the solution and adding 75 mM N~C03' 
2.2.14 Agarose Electrophoresis of DNA 
Agarose "sub-cell" gel tanks were supplied by Pharmacia. Nucleic acid grade "ultrapure" 
agarose (BRL) or molecular grade (Sigma) was used at concentrations of 1 - 1.2% 
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Figure 2.5 KB Ladder 
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(w/v) in Loening "E" buffer. Ethidium bromide (Et Br) was added to molten agarose at 
a final concentration of 0.2 flg ml-I. DNA loading buffer (0.1 % (w/v) bromophenol blue, 
0.25% (w/v) xylene cyanol, 75 mM EDTA, 25% sucrose) was added 1 : 9 (v/v) to 
samples prior to loading, and electrophoresis was carried out at 2 - 5 volts cm- I in 
Loening "E" buffer until the required resolution was achieved. Co-electrophoresis of a 1 
Kb ladder (Gibco - BRL) permitted the estimation of band size (Figure 2.5). 
2.2.15 Southern Blotting of DNA to Nylon Membranes 
DNA was transferred from agarose gels to nylon membranes using a modification of the 
method of Smith and Summers (1980). The gel was denatured in 0.5 M Na OH, l.5 M 
NaCl for 30 minutes, and then neutralised in 1 M ammonium acetate for 1 hour. 
"Hybond N" nylon membrane (Amersham) was then placed on top of the gel followed by 
3 sheets of What man 3MM chromatography paper which had been soaked in neutralising 
solution. A further 3 sheets of dry chromatography paper were added, and finally a 3 cm 
stack of paper towels and a 1 kg weight were placed on top of the membrane. Transfer 
was carried out over 3 - 18 hours. The filter was then washed in 2 x SSC, dried, and the 
DNA fixed to the membrane by ultra-violet (UV) irradiation (0.4 J cm- I ). 
2.2.16 Preparation of Digoxigenin Labelled DNA Probes 
PCR products were labelled with digoxigenin (DIG) using the "DIG DNA labelling and 
detection kit" (Boehringer Mannheim). A fragment of 96 bp (using primers P2 and P3) 
was used for the Bl system, and a fragment of 522 bp (using primers DS38 and DS39) 
for the P30 system. The DNA was denatured by boiling for 10 minutes, then incubated 
with 1 fll random hexanucleotide mix, 1 fll dNTP labelling mix and 1 unit of Klenow 
enzyme for 2 - 16 hours at 37°C. This labelling reaction results in the random 
incorporation of DIG - 11 - dUTP every 20 - 25 nucleotides in the newly synthesised 
DNA (Feinberg and Volgenstein 1983). 
Alternatively, PCR was used to prepare large quantities of DIG - labelled probes. PCR 
reactions were carried out as described in 2.2.10 and 2.2.11, with DIG- dUTP 
incorporated into the 2 mM dNTP xl0 stock at a ratio of35 : 65 (DIG - dUTP : dNTP). 
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2.2.17 Hybridisation of DIG Labelled Probes 
Hybridisations were carried out as recommended by the manufacturers (Boehringer 
Mannheim). Filters were prehybridised by incubating in hybridisation solution (5 x SSC, 
5% (w/v) "blocking reagent" , 0.1% (w/v) N- lauroylsarcosine Na- salt, 0.02% (w/v) 
SDS, 50% (v/v) formamide) for 1 hour at 42°C. Freshly denatured probe was then 
added (2 - 5 Ill) and hybridisation was carried out for 2 - 16 hours at 42°C. Filters were 
washed twice in 2 x SSC, 0.1% (w/v) SDS for 5 minutes, then twice in 0.1 x SSC, 0.1% 
(w/v) SDS for 15 minutes at 68°C. 
2.2.18 Detection of Bound DIG Labelled Probes 
All steps were carried out at room temperature. Filters were washed briefly in Buffer 1 
(100 mM Tris, 150 mM NaCl) and then blocked in Buffer 2 (Buffer 1 with 0.5% (w/v) 
"blocking reagent") for 30 minutes. After washing, the filters were incubated in 10-20 
ml of Buffer 1 containing 1:5000 (v/v) dilution of anti-DIG alkaline-phosphatase 
conjugate for 30 minutes. Any unbound conjugate was removed by washing twice in 
Buffer 1 for 15 minutes. The filters were then equilibrated in Buffer 3 (100 mM Tris-
HCI, 100 mM NaCI, 50 mM MgC~ pH 9.5) and a colour solution was added which 
consisted of 45 III "NBT" solution (75 mg ml- I nitroblue tetrazolium salt in 
dimethylformamide), and 35 III "x-phosphate" (50 mg ml- I in 5- bromo-
4-chloro-3-indolylphosphate, toludinium salt in dimethylformamide) in 20 ml Buffer 3. 
The filters were incubated in the dark for 1 - 24 hours until the colour developed. The 
reaction was stopped by washing briefly in TE and the filters were air dried. 
2.3 MATERIALS AND METHODS FOR THE ANTIGEN ELISA 
2.3.1 Antigen Preparation 
Soluble T. gondii antigen was obtained by freezing and thawing a clean tachyzoite 
suspension (2.2.2) three times. Particulate matter was then removed by centrifugation at 
10000 g for 30 minutes and the soluble fraction stored at -20°C until required. 
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2.3.2 Raising Antibody 
Three New Zealand White rabbits were inoculated intramuscularly with 4 x 105 S48 
tachyzoites from mouse peritoneal exudates in Freund's incomplete adjuvant. Blood was 
collected from each every two weeks and the serum separated and tested by IF AT until 
the IgG antibody titre reached 1: 64 000. IgG in the serum was extracted by passing 
pooled serum through a Staphylococcal protein A column (Goding 1976). The column 
was washed with PBS and the IgG fraction was eluted out with 0.58% glacial acetic 
acid containing 0.15 M sodium chloride. Ultra-violet absorption was used to identify the 
IgG peak and the corresponding fractions were collected and dialysed overnight at 4°C 
with PBS, and stored at -20°C. 
2.3.3 Commercial Antibody 
Monoc1onal anti- T. gondii antibody was supplied by Quadratech. 
2.3.4 Conjugate 
Horseradish Peroxidase (HRP) conjugated to the IgG molecule had been prepared earlier 
(Maley 1991) using the method ofWilson and Nakane (1978). Briefly, Grade VI HRP 
(Sigma) was added to sodium meta periodate and the resulting aldehyde was dialysed 
against 1 mM sodium acetate buffer (pH 4.4) overnight at 4°C. Sodium carbonate (pH 
9.5) was then added to raise the pH of the solution to pH 9. Rabbit anti- Toxoplasma 
serum was added (2 rnl fractions), and the mixture was incubated at room temperature 
for two hours. Sodium borohydrate (0.4 mg rnI-) was then added and incubated at 4°C 
for two hours. Absorbance readings were taken at 280 nm and 403 nm and the best 
fractions were pooled and bovine serum albumin (BSA) was added to 10 mg rnI-1. The 
conjugate was then divided into 0.5 rnl aliquots and stored at -20°C. 
2.3.5 Assay Procedure 
Dynatech M129B plates were coated with 150 f..I.I of rabbit anti-IgG antibody diluted at 
1:4000 in 0.1 M carbonate / bicarbonate buffer (pH 9.6). Commercial monoc1onal 
antibody (2.3.3) was used at 1: 500. Plates were incubated overnight at 4°C and then 
washed three times in PBS containing 0.05% Tween 20 (PBST). A series of control 
r 
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antigen dilutions (doubling dilutions from 1 : 200 to 1: 25 600 ) were included, and 150 
~l of serum or control was added to the appropriate well and the plates were incubated 
at 37°C for two hours. After three washes with PBST, rabbit anti- T. gondii IgG was 
added at 1 : 5 000 in PBST containing 1% BSA and incubated at 37°C for a further two 
hours. The plates were again washed and 150 ~l ofO-Phenylenediamine (OPD) substrate 
was added for 30 minutes. The substrate consisted of 40 mg OPD in 100 ml phosphate 
citrate buffer (0.02 M citric acid, 0.05 M sodium hydrogen phosphate pH 5) plus 40 ~l 
hydrogen peroxide. The reaction was stopped using 50 ~l 2.5 M sulphuric acid and the 
plates were read using a 492 nm filter on a Titretek ELISA reader. 
2.3.6 Samples 
As well as using a range of diluted antigen controls and dilutions containing from 1-1000 
parasites (approximately, see 2.4), ELISA was carried out on samples from sheep 
experimentally infected with 105 Toxoplasma tachyzoites and from patients showing 
clinical signs of toxoplasmosis. 
2.3.7 Acid Dissociation of Samples 
150 ~l of serum was added to 150 ~l of l.5 M glycine (pH l.85). After vortexing, the 
mixture was incubated at 37°C for 1 hour and then neutralized with 150 ~l of 1.5 M Tris 
(pH9). The ELISA was then carried out using 150 ~l of this sample using the procedure 
in 2.3.5 differing only in sample incubation time which was increased from 1 hour to 
overnight at 37°C. 
2.4 COMPARISON OF THE PCR AND ELISA 
Both antigen ELISA and PCR were used against a panel of control samples infected with 
a known amount of T. gondii parasites (200 ~l PBS containing 1000, 500, 100, 50, 10, 
5, or 1 parasites). Samples were used neat for ELISA using the protocol in 2.3.5. DNA 
was phenol/chloroform extracted and ethanol precipitated (2.2.3) for use in Bl and 
P30 PCR (2.2.10 and 2.2.11). 
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2.5 RESULTS 
2.5.1 Sensitivity of the peR 
When P30 PCR was used against a titration of T. gondii DNA controls, the system was 
found to detect down to 0.5 pg on a 1% agarose gel (Figure 2.6). This sensitivity was 
improved by southern blotting to detect 0.05 pg of DNA (Figure 2.7). The B1 PCR 
appeared to be slightly more sensitive than P30 as 0.05 pg could often be detected as a 
faint band on 1% agarose gels (Figure 2.8). This was not further improved by Southern 
blotting, although bands were more intense (Figure 2.9). However the result was often 
difficult to interpret because of the close proximity of the 96 bp product to the primer 
haze which was often present when the sample was run on a gel (2.10). Bands were 
therefore better differentiated by PAGE (Figure 2.11). 
2.5.2 Specificity of the peR 
DNA from CMV, Candida albicans, Sarcocystis spp., Pneumocystis carinii and 
Aspergillusjumigatus did not result in amplification products by B1 or P30 PCR. 
2.5.3 Optimisation of the peR 
As was described in 2.2.10 and 2.2.11 it was possible to optimise both PCR systems to 
detect low levels of parasite. Because the nested primers (P2 and P3) produced a 
fragment of only 96 bp in the B 1 PCR which was difficult to differentiate from the 
primer haze on agarose, the nested amplification was carried out using PI and P3 to give 
a product of 158 bp which was easier to differentiate. An additional problem was the 
number of artefact bands which were present when products were run on a gel although 
these bands were not present after Southern blotting. This problem was overcome by 
including a dilution step between the initial amplification and the nested amplification. A 
dilution factor of 1 :20 in water was sufficient to reduce the amount of background bands 
to a negligible level. 
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Figure 2.6 P30 PCR products by agarose gel electrophoresis (Et. Br) using decreasing amounts 
of T. gondii DNA template. Products were detected down to 0.5 pg. 
522 bp 
KB - 1 0.8 0.5 0.1 0.05 0 
pg pg, pg pg pg 
Figure 2.7 P30 PCR products by Southern blot from agarose gel (Figure 2.6) showing an 
increase ill sensitivity to detect 0.05 pg 
o 
o 0.05 0.1 0.5 0.8 1.0 
pg pg pg pg pg 
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Figure 2.8 BI PCR products by agarose gel electrophoresis (Et. Br) using decreasing 
amounts of T gondii DNA template. 
94 bp 
KB 1.2 1.0 0.8 0.5 0.2 0.1 0.05 0 
pg pg pg pg pg pg pg 
Figure 2.9 BI PCR products by Southern blot from agarose gel (Figure 2.8). 
o 0.05 0.1 0.2 0.5 0.8 1.0 1.2 
pg pg pg pg pg pg pg 
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Figure 2.10 BI peR products by agarose gel electrophoresis using different primer 
combinations. 
1 
Lane 1: PI + P4 (193 bp) 
Lane 2: PI + P3 (159 bp) 
Lane 3: P2 + P3 (96 bp) 
Lane 4: P2 + P4 (130 bp) 
2 3 4KB 
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Figure 2.11 B I peR products by PAGE using different primer combinations 
Lane 1: PI + P4 (193 bp) 
Lane 2: PI + P3 (159 bp) 
Lane 3: P2 + P3 (96 bp) 
Lane 4: P2 + P4 (130 bp) 
3 4 1\.13 
47 
CHAPTER 2 48 
It was possible to reduce the running time of the reactions by decreasing the time for 
each stage of the cycles and still obtain the sensitivity to detect 0.05 pg DNA. The final 
cycle regime used for the B 1 PCR was 95°C for 20 seconds, 50°C for 20 seconds and 
72°C for 40 seconds. This reduced the total running time from 3 hours to 1 hour 45 
minutes for each amplification. There was also a reduction in time for the P30 PCR from 
3 hours to 1 hour 55 minutes for each amplification. The final regime was 95°C for 40 
seconds, 60°C for 40 seconds and 72°C for 1 minute. 
2.5.4 Antigen ELISA 
The ELISA using polyclonal antibody did produce a good standard curve of absorbance 
against dilution using antigen controls (Figure 2.12). However when the test was used 
on 10 samples from clinically infected sheep, none of the samples could be considered 
positive as all absorbance readings were below that of the standard curve. Similar 
negative results were obtained with 20 samples from patients with clinical symptoms of 
toxoplasmosis, although samples showed slightly raised levels. Acid dissociation of 
antigen / antibody complexes did increase the absorbance readings of sera, but did not 
detect any positive results with the samples used in this study (Figure 2.13). 
Commercially produced mono clonal IgG produced a similar standard curve with antigen 
controls. However results were more promising as serum samples from two patients with 
clinical toxoplasma encephalitis were within this curve and could be considered positive, 
although these were at the lower end of the range (Figure 2.14). 
2.5.5 Comparison of the PCR and ELISA 
The PCR successfully amplified DNA from T. gondii in control samples down to 0.05 pg 
DNA, which is approximately equal to one parasite (Savva et al. 1990). The B 1 PCR 
detected parasite at this level in 2 out of 3 cases on 1 % agarose and by Southern 
blotting. P30 detected parasite at this level in lout of 3 cases by Southern blotting, 
although the band could not be seen on 1 % agarose. 
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Figure 2.12 Antigen ELISA. Standard curve (best fit) of absorbance against dilution using 
antigen controls. 
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Figure 2 .13 Antigen ELISA. Standard curve (best fit) of absorbance against dilution using 
antigen controls after acid dissociation of antigen / antibody complexes. 
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Figure 2.14 Antigen ELISA. Standard curve of absorbance against dilution with antigen 
controls using commercially produced monoclonal IgG. The results from the two 
patient sera which were positive are shown. 
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ELISA detected 500 parasites when monoclonal antibody was used to coat the plates, 
and only 1000 parasites when using polyc1onal antibody. It did not detect parasite at 
lower levels (100, 50, 10, 5 or 1). 
2.6 DISCUSSION 
The antigen ELISA proved to be disappointing in its inability to detect T. gondii 
infection in both control samples and clinical samples, although the use of monoclonal 
antibody did improve performance to a level where infection was detected in two out of 
20 clinical samples. The low sensitivity of the ELISA has also been reported by others 
using polyclonal sera or fractions of polyclonal sera. For example, van Knapen and 
Panggabean (1977) reported a detection rate as low as 5.7% in sera from individuals 
suspected of having acute toxoplasmosis. Antigenaemia was detected by Candolfi et at. 
(1987) in only 7 out of 22 patients who later seroconverted or showed clinical signs of 
toxoplasmosis. Araujo and Remington (1980) did demonstrate cag in 65% of patients 
with recently acquired toxoplasmosis by using affinity purified F(ab)2 fragment to coat 
the plate. This may improve the sensitivity of the system, but it is unlikely to significantly 
increase performance. When this system was used by Hassl et at. (1988) antigen was 
detected in only 16% of AIDS patients and so they questioned the significance of cag in 
this population. 
There may also be problems with interference by the presence of antigen-antibody 
complexes in the ELISA system (Hassl et al. 1988). Van Knapen et al. (1985) used an 
ELISA system to detect specific T. gondii complexes and obtained a positivity rate of 
12.5% in individuals suspected of having toxoplasmosis. Lindenschmidt (1985) included 
an extra step to dissociate antigen-antibody complexes with 3 M NaSCN. This 
technique showed 30% of acute phase sera to be positive, compared to only 5% when 
the method of van Knapen et al. (1985) was used. Acid dissociation of these complexes 
did not improve the rate of positive results in this study. 
The PCR performed well in the control specimens tested in this study. Both the Bl and 
P30 systems were sensitive, with the ability to detect down to the equivalent of only one 
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parasite. Although this degree of sensitivity was not possible on every occasion, this was 
likely to be due to sampling variation. Parasite numbers were recorded and then diluted 
to the various testing levels. At such low levels it would be possible to have no parasite, 
or one or two parasites in the small sample tested by the PCR. Both systems were also 
specific when tested against other organisms. 
The sensitivity of the PCR was substantially better than that of the ELISA for the 
detection of T. gondii in the control samples. Although some factors of the ELISA, such 
as the use of monoclonal antibody may be improved to increase the sensitivity of the 
system, the ability to locate and amplify specific pieces of T. gondii DNA make the PCR 
the most effective method for use as a diagnostic tool. It was therefore decided to 
discontinue work on the ELISA in order to concentrate on the PCR. 
The samples tested so far have been "spiked" buffer controls but it is necessary to carry 
out tests using clinical samples. Several studies have successfully used the Bland P30 
PCR to detect parasite in certain clinical samples (for example Weiss et al. 1991, van de 
Yen et al. 1991, Holliman et al. 1990b). However these have lacked controls in using 
only samples from patients with suspected toxoplasmosis. The sensitivity of either system 
has not been previously been demonstrated using controlled clinical samples. The next 
stage of this study therefore attempted to address this point. 
CHAPTER 3 
A Comparison of the Bl and the P30 
Polymerase Chain Reaction 
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3.1 INTRODUCTION 
Both the B 1 and the P30 PCR were shown to amplify purified DNA from T. gondii 
(chapter 2). These systems were also successful when used by Turner et al. (1991), Burg 
et al. (1989) and GroB et al. (1992) in studies using limited samples. However none of 
these investigations included clinical samples from infected subjects studied over a 
significant time course, or included confirmation using other systems such as MI. In 
order to assess the suitability of the B 1 and the P30 PCR for the detection of T. gondii 
in clinical samples, it was necessary to apply these techniques in controlled experimental 
conditions. 
This study involved the comparison of the B1 and the P30 PCR by following the course 
of infection in sheep experimentally infected with T. gondii. The aim of the study was to 
establish whether one of the PCR methods was more suitable for use with clinical 
samples, and to compare the performance of this methodology against MI. Mouse 
inoculation is currently regarded as the most sensitive and accurate diagnostic test as it 
is believed that only one parasite is necessary to cause illness in an inoculated animal. It 
is therefore the 'gold standard' to compare against PCR. 
As the B 1 system targets a multi copy gene, it was hypothesised that this would be more 
sensitive than P30, which amplifies a single copy gene. Initial studies (chapter 2) revealed 
the B 1 PCR to be more sensitive than the P30 PCR in the detection of purified DNA 
from a single parasite when viewed on an agarose gel, but both displayed equal 
sensitivity using Southern blot analysis. 
In the second part of this study samples of blood, lymph and tissue were investigated for 
their suitability for the detection of T. gondii. Haemoglobin in blood is known to inhibit 
the PCR (van de Yen et al. 1991, Weiss et al. 1991, Joss et al. 1993), therefore three 
preparation methods were investigated to identify an appropriate system for 
amplification. 
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3.2 MATERIALS AND METHODS 
3.2.1 Parasite Preparation 
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S48 tachyzoites were cultured as described In 2.2.2. Preparations containing 98% 
tachyzoites were used to inoculate sheep. 
3.2.2 Samples 
Scottish Blackface ewes (n=9) which were seronegative for T. gondii by IgG ELISA 
(Buxton et al. 1988) were inoculated with approximately 105 S48 tachyzoites by 
subcutaneous injection. Efferent lymph was collected from six animals following surgical 
cannulation of the pre-femorallymph duct (Buxton et al. 1994 in press, see Appendix 11) 
for MI, and for the Bland P30 PCR. Peripheral blood samples were collected from the 
remaining three non-cannulated sheep for PCR only. Samples were taken prior to 
infection and then every 24 hours for 15 days post infection (p.i.). Tissue samples of 
brain, spleen, lymph nodes, diaphragm, liver and kidney were obtained at post mortem 
examination from one animal in which the cannula failed 12 days p.i .. 
3.2.3 Sample Preparation 
Lymph samples were diluted 1: 10 with PBS to prevent clotting and centrifuged at 800 g 
for 10 minutes. Contaminating red blood cells (RBC's) were removed using osmotic 
shock by resuspending the cell pellet in 10 mM Tris ammonium chloride (pH 7.2), 
followed by 3 washes in PBS. The pellet was then resuspended in 50 III ofK buffer (lOO 
mM Tris pH 8.3; 500 mM potassium chloride; 15 mM magnesium chloride; 0.5% 
Tween 20) containing 100 Ilg ml-1 proteinase K. After incubating at 55°C for one hour 
the enzyme was inactivated by boiling for 10 minutes after which the samples were 
stored at -20°C until ready for use. 
Blood samples were prepared using three methods: 
1) Collection of the buffy coat from heparinised blood by centrifugation at 800 g over 
lymphoprep (Nycomed, Oslo). The Remaining RBC's were removed using 10 mM Tris 
ammonium chloride (pH 7.2) followed by centrifugation at 13 000 g for 30 seconds. The 
pellet was then resuspended in K buffer containing proteinase K and treated as above. 
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2) Dilution of SO-lOO ~l of blood in 10 mM Tris ammonium chloride (pH 7.2) to lyse 
RBC's, followed by centrifugation at 13 000 g for 30 seconds. The pellet was 
resuspended and washed a further two times before being resuspended in K buffer 
containing proteinase K and treated as above. 
3) Dilution of SO-lOO ~l of blood in O.S ml of water and then boiling for 20 minutes. 
Tissue samples, frozen prior to treatment, were finely dissected and washed in PBS. 
RBC's were removed as before and the tissues digested overnight at 37°C in 1 00 ~l of SO 
mM Tris (pH 8.S), 1 mM EDTA, O.S% Tween 20 containing 200 ~g ml-1 proteinase K. 
The enzyme was then inactivated, and the samples stored as before. 
3.2.4 The peR 
This was carried out as described in 2.2.9 - 2.2.11. 
3.2.5 Mouse Inoculation 
Three female Swiss White mice were each inoculated with 2S0 ~l of lymph by i.p. 
injection for each sample tested. The animals were inspected daily for signs of a febrile 
response that may indicate acute toxoplasmosis. Animals which appeared ill were culled 
immediately and a sample of peritoneal exudate removed and inspected for tachyzoites 
by microscopic examination. Mice which survived were culled at 8 weeks post 
inoculation and the presence of T. gondii antibodies detected by IgG ELISA (Buxton et 
al. 1988). (Work carried out by J. Wastling). 
3.2.6 Statistical Analysis 
A generalised linear model with a binomial error term (McCullagh and Nelder, 1983) 
was used to analyse data for parasite detection in lymph by PCR and MI. This was 
programmed in the Genstat S programming language (payne et al. 1988). Parasite 
detection in blood by the Bland P30 PCR was compared by a two-tailed t test. 
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3.3 RESULTS 
3.3.1 Parasite Detection in Efferent Lymph 
Table 3.1 shows MI and PCR results obtained from lymph from two cannulated animals 
which were typical of the group. It can be seen that samples were negative by both MI 
and PCR for three to five days p.i .. Detection by MI took longer than PCR in animal 1, 
and samples were positive for only three days. In animal 2, MI detected parasite over 
nine days, although at the periphery of the detection period this was often in only one or 
two out of three mice inoculated. It was these results which were discrepant with the B 1 
PCR. The P30 PCR detected parasite over only three days in this animal, whereas the B 1 
method was positive over seven days. 
A total of 101 lymph samples were collected in the period from 4 days prior to infection 
to 15 days p.i .. The number of positive tests given by MI and the Bl and P30 PCR are 
shown in Table 3.2. MI detected parasite in 29 samples, whereas the Bl PCR detected 
30 positive samples, and the P30 method only 20. All mice which survived inoculation 
were T. gondii IgG negative by ELISA. The mean number of days in which positive 
results were obtained was 4.8 (SD 3.2) days with MI, 5.0 (SD 1.9) days with the Bl 
PCR, and 3.2 (SD 2.2) days with the P30 PCR. 
Table 3.3 shows how these methods of detecting T. gondii compared against each other. 
The Bl and P30 PCR were compared with MI for each lymph sample. MI detected 
parasite in 23 samples which were also positive by the B 1 PCR. However the P30 PCR 
detected parasite in only 14 of these samples. The overall reliability of PCR detection 
compared to MI was 87% using the B 1 target and 79% using the P30 target. When 
frequency of parasite detection by the two PCR methods was compared to only the 29 
samples which were MI positive, the agreement between the PCR and MI was 79% for 
the B 1 system and only 48% for the P30 system. 
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Table 3.1 T. gondii detection in efferent lymph by MI, Bl PCR and P30 PCR in animals 
1 and 2. 
Animal 1 Animal 2 
Day p.i. MI* Bl P30 MI* Bl P30 
-4 0 - - 0 - -
-3 0 - - 0 - -
-2 0 - - 0 - -
-1 0 - - 0 - -
0 0 - - 0 - -
1 0 - - 0 - -
2 0 - - 0 - -
3 0 - - 1 - -
4 0 - - 2 + + 
5 0 + + 3 + + 
6 0 + - 3 + + 
7 3 + + 3 + -
8 3 + + 3 + -
9 3 + + 3 + -
10 0 - - 1 - -
11 0 - - 1 - -
12 0 - - 0 + -
13 0 
- - 0 - -
14 0 - - 0 - -
15 0 - - 0 - -
59 
'" Numbers represent mice (n=3) culled due to acute toxoplasmosis following i.p. inoculation with 
250 Jlllymph. 
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Table 3.2 Comparison ofMI and the Bl and P30 PCR for detection of T. gondii in lymph from 
infected sheep. 
Day p.i. Number of sheep tested MI BIPCR P30PCR 
-4 2 0 0 0 
-3 4 0 0 0 
-2 5 0 0 0 
-1 5 0 0 0 
0 6 0 0 0 
1 6 0 0 0 
2 6 0 0 0 
3 6 2 1 2 
4 6 4 4 5 
5 6 4 6 3 
6 6 4 5 2 
7 6 5 4 2 
8 5 4 4 2 
9 5 4 3 2 
10 5 1 1 1 
11 5 1 1 1 
12 5 0 1 0 
13 5 0 0 0 
14 5 0 0 0 
15 2 0 0 0 
Total 101 29 30 20 
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Table 3.3 T. gondii detection in ovine efferent lymph by the Bl and P30 PCR compared with 
MI. Data represents combined results from six animals (101 samples). 
Bl P30 
Positive Negative Positive Negative 
Positive 23 6 14 15 
MI 
Negative 7 65 6 66 
Table 3.4 Detection of T. gondii in blood samples from three non-cannulated sheep by the 
PCR. 
Day p.i. 
Sheep peR 1 2 3 4 5 6 7 8 9 10 11 12 13 
A Bl - - - - - + + + + + - - -
P30 - - - - - - + + - - - - -
B Bl - - - - - + + + + - - - -
P30 - - - - - - + + - - - - -
C Bl - - + - - + + + - - + - -
P30 
- - - - - - + - - - - - -
14 
-
-
-
-
-
-
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3.3.2 Parasite Detection in Blood 
In initial studies using blood samples from animal A parasite was detected in five out of 
nine buffy coat samples, in four whole blood preparations, and in only one boiled 
preparation. As a result, the buffy coat was used for the remainder of blood samples 
processed in this study. Preparation methods for human blood samples is investigated in 
chapter 4. 
The results for the blood samples from the three non-cannulated animals are presented in 
Table 3.4. Parasitaemia was detected earlier with the Bl than with the P30 PCR in all 
animals. The Bl gene was detected over a mean of 4.7 (SD 0.6) days compared to a 
mean of 1.7 (SD 0.6) days with the P30 gene (p=0.003, 4 df, two-tailed t test). 
3.3.3 Parasite Detection in Tissue 
T. gondii was detected by both the Bland P30 PCR in the left and right pre-femoral 
lymph nodes from the sheep killed 12 days p.i .. However samples of liver, spleen, brain, 
kidney and diaphragm were negative by both methods. 
3.4 DISCUSSION 
Both the Bl and P30 PCR were capable of detecting T. gondii in samples of blood, 
lymph and tissue from experimentally infected sheep. However the relative sensitivity of 
these systems differed. Parasite was detected earlier and over a significantly longer 
period in samples of peripheral blood using the B 1 PCR. When compared with MI in 
lymph samples, parasite detection was significantly higher with the B 1 PCR than with 
the P30 PCR. Discrepancies between MI and the Bl PCR occurred at the periphery of 
the detection period where parasite numbers were presumably low. A larger sample 
volume (250 Ill) was used to inoculate each of three mice used for every sample, 
compared to a small 5 III aliquot from a 50 III sample preparation for the PCR, therefore 
sampling error may account for some of the discrepancies seen between MI and PCR. It 
is possible that accuracy of the test could be improved by repeating the amplification 
reactions on three occasions, on a similar basis to MI. This would detect the parasite at 
very low levels, for example when it is present in only one or two out of three aliquots. 
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In a small number of samples the Bland P30 PCR detected parasite where MI did not. 
This may be explained by the ability of the PCR to detect non-viable parasites which 
would not be identified by MI. Therefore it seems likely that the PCR is capable of 
detecting parasite DNA from dead organisms after their defeat by the host immune 
system. The possibility that these results were false positives seems unlikely as none of 
the large number of negative controls used in each run were positive. In addition, none of 
the samples of blood or lymph taken before inoculation were positive by either PCR 
method. 
Samples of blood and lymph used in this study were found to be suitable for PCR 
analysis. However of the various tissue types tested, only lymph node samples produced 
positive results. As the parasite is known to encyst in a wide variety of different tissue 
types, it would be likely that experimental infection with such a large number of parasites 
would increase the chance of detecting DNA from tissue cysts in these animals. Weiss et 
al. (1992) reported that tissue which had been frozen prior to PCR analysis was 
unreliable when compared to detection in paraffin-embeded tissues for unknown reasons. 
It is impossible to reject this as a reason for the negative results from most of the tissues 
tested in this study. However the S48 strain used in this study is an incomplete form of 
the parasite, only existing as the tachyzoite and is unable to encyst in tissues (Buxton 
1990, Buxton et al. 1991). It is likely that the PCR amplified DNA from tachyzoites 
present in the lymph node, or in the lymph fluid itself, while there was no amplification 
from other tissues because of the lack of tissue cysts in these animals. It is therefore 
necessary to test other tissue samples from animals infected with different strains of T. 
gondii using a larger number of animals. 
The initial hypothesis that the B 1 PCR was likely to be more sensitive than the P30 PCR 
was confirmed and this can be explained by the repetitive nature of the target gene. This 
was also suggested by Brezin et al. (1990) as the reason for the success of the B 1 PCR 
and the failure of the P30 system in the detection of human ocular toxoplasmosis. These 
results indicate that the B 1 PCR should be the system of choice in detecting T. gondii in 
clinical samples, and demonstrates its value as a diagnostic tool. 
CHAPTER 3 64 
The PCR has added benefits over MI because of the reduction in time needed to obtain a 
result from six weeks to one day. This would result in significant changes to treatment 
regimes in the infected host, with an earlier start to therapy. It also negates the need for 
large numbers of mice. 
CHAPTER 4 
T. gondii Infection in the Human Host 
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4.1 INTRODUCTION 
Following the success of the PCR to detect T. gondii infection in controlled 
experimental conditions the techniques were applied to samples from patients. The main 
part of the study investigated infection in AIDS patients as immunosuppression and 
illness progressed. However, immunocompetent patients suspected of having 
toxoplasmosis were also investigated. 
AIDS patients are at risk from reactivation of a latent infection as the disease progresses 
and their CD4+ cell count falls below 100 mm-3. Opinion is currently divided over 
whether T. gondii recrudescence is due to haematogenic spread (Luft and Remington 
1992, Dannemann et al. 1991), or to local reactivation (Hassl et al. 1988, Navia 1986). 
If reactivation is localised, the chance of detecting parasite using PCR in samples such as 
blood (and therefore diagnosing infection) is low. However, if the infection is spread 
through the blood, parasite may be detectable before clinical signs of infection appear. 
This early detection would be of great value diagnostically, and would also aid the 
initiation of treatment, which if given early enough, may prevent the development of 
encephalitis and other illness. 
PCR may also be valuable in monitoring the effects of treatment. For example, if initial 
therapy is successful the dose may be reduced to a maintenance level, with samples then 
being tested for further signs of recrudescence. It may therefore be possible to reduce 
maintenance therapy to less toxic levels which would still be capable of preventing 
relapse. 
Published work on the use of PCR for T. gondii detection has involved the use of 
samples such as brain biopsy, CSF and blood (see 1.9.2), but these have involved 
different methods and complexities of preparation from those investigated here. Blood 
samples have been treated in a variety of ways, from merely boiling the sample in water 
to lyse cells (Joss et al. 1993, Ho-Yen et al. 1992), to proteinase K digestion (van de 
Yen et al. 1991), and also full DNA extraction procedures (Johnson et al. 1993). These 
methods have involved the use of whole blood or buffy coat samples as starting material. 
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It has been argued that complex sample preparation methods may result in the loss of 
small amounts of DNA, and that as a result low levels of infection could be missed. 
Alternatively, simple techniques such as boiling may minimise preparation time and 
handling, but may have problems with the presence of haemoglobin which is inhibitory to 
PCR. Several blood preparation methods were therefore investigated. 
There were several aims of this study. Firstly to investigate the suitability of different 
sample types for use in PCR. If blood and urine could be used successfully, they would 
negate the need for more invasive procedures such as brain biopsy and lumbar puncture. 
Secondly, preparation methods were investigated with the aim of developing a system 
which would be both sensitive and involve minimal preparation. The effects of inhibitory 
factors (Grover et al. 1990) were also considered. 
4.2 MATERIALS AND METHODS 
4.2.1 Patients 
mv infected patients from the Regional Infectious Disease Unit in Edinburgh were 
enrolled in this study when their CD4+ cell count fell below 100 mm-3, or if toxoplasma 
encephalitis was suspected on clinical grounds. Patients were assigned to one of three 
groups and followed prospectively. 
Group 1 consisted of individuals with a CD4+ cell count less than 100 mm-3 and positive 
baseline T. gondii serology. Group 2 patients had negative T. gondii serology and CD4+ 
cell count less than 100 mm-3, and Group 3 patients had clinical indications of T. gondii 
infection. 
Patients in Groups 1 and 2 were identified at each clinic visit. Patients in Group 3, with 
clinical toxoplasmosis were generally investigated as in-patients and followed up after 
treatment at each clinic visit. 
Patients in other risk groups were also included in this study when toxoplasmosis was 
suspected, or when it was necessary to exclude toxoplasmosis as a cause of symptoms. 
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4.2.2 Samples 
Samples of blood and urme were taken routinely at each clinic visit, or when 
toxoplasmosis was suspected. Other samples such as CSF and tissue were also obtained 
when appropriate as part of the investigation of symptoms. A collection of post mortem 
samples from mv positive individuals was also investigated. All samples were tested 
using Bland P30 PCR. 
4.2.3 Sample Preparation 
Blood 
Preservative-free heparinised blood was divided into three to five aliquots, depending on 
the volume obtained. The aliquots used were as follows: (1) 5 ml for white blood cell 
(WBC) preparations; (2) 100 III for a boiled preparation; (3) 100 III for a whole blood 
(WB) preparation; (4) 5-10 ml for a Nucleon preparation (Scotlab); (5) Any remaining 
sample was stored. 
A preliminary investigation was carried out to outline the effectiveness of four blood 
preparation methods. These methods were compared using ten samples from T. gondii 
antibody positive patients, five of whom had clinical toxoplasmosis, and ten samples 
from T. gondii antibody negative patients. 
1) Proteinase K digestion of buffy coat (WBC Preparation) 
A similar method to that described in 3.2.3 (1) was used where buffy coat was collected 
from heparinised blood by centrifugation at 800 g over lymphoprep (Nycomed, Oslo). 
Remaining RBC's were removed using TE rather than 10 mM Tris ammonium chloride. 
This was followed by centrifugation at 13 000 g for 30 seconds. The pellet was then 
resuspended in K buffer containing proteinase K and treated as previously described 
(3.2.3). 
2) Boiled blood preparation 
(see 3.2.3). 
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3) Proteinase K digestion of whole blood (WB Preparation) 
This was again similar to the method described in 3.2.3, with TE used to remove RBC's 
from 100 III of blood instead of 10 mM Tris ammonium chloride. This was followed by 
centrifugation at 13 000 g for 30 seconds and a further two washes with TE. The pellet 
was finally resuspended in K buffer containing proteinase K as before. 
4) Nucleon preparation 
Following the manufacturer's instructions (Scotlab), 5 to 10 rnl of heparinised blood was 
added to 40 rnl of reagent A (10 mM Tris, 320 mM sucrose, 5 mM MgCI, 1 % Triton 
x-lOO (pH 8.0)). This was agitated at room temperature for four minutes, followed by 
centrifugation at 1300 g for four minutes. The supematant was discarded and the pellet 
was resuspended in 2 rnl of reagent B (400 mM Tris (pH 8.0),60 mM EDTA, 150 mM 
NaCl, 1 % SDS), and transferred to a capped 5 rnl polypropylene tube. After the addition 
of 500 III of 5 M sodium perchlorate the tube was mixed at room temperature for 15 
minutes and then at 65°C for 25 minutes. DNA was extracted by the addition of 2 rnl of 
cold chloroform and mixing at room temperature for ten minutes, followed by 
centrifugation at 800 g for one minute. Nucleon silica suspension (300 Ill) was added and 
then the preparation was centrifuged at 1400 g for three minutes. The top layer was 
transferred to a fresh tube and the DNA precipitated by the addition of cold (4°C) 100% 
ethanol. After centrifugation at 13 000 g for ten minutes the pellet was resuspended in 50 
III K buffer. 
CSF 
Processing was based on the method of Lebech et al. (1992). An aliquot of 100 III of 
CSF was boiled for 15 minutes using the Techni thermal cycler, after which DNA was 
precipitated by the addition of 250 III 100% ethanol at -20°C for one hour. The DNA 
was collected by centrifugation at 13 000 g for 30 minutes, and the resulting pellet 
washed with 70% ethanol. After further centrifugation the pellet was dried and 
resuspended in 20 III of distilled water. 
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Urine 
Urine was divided into two 1 ml aliquots, one was stored and the other was processed as 
follows. After centrifugation at 13 000 g, the pellet was washed three times in saline 
solution and digested in K buffer containing 100 J.lg ml-1 proteinase K as previously 
described (3.2.3). 
Tissue 
Tissue samples were prepared as described in 3.2.3, using TE in place of 10 mM Tris 
ammonium chloride (pH 7.2) to remove contaminating RBC's. 
Post Mortem Samples 
All samples were stored at -70°C prior to processing. After thawing, samples were 
treated as described for tissue above. 
All prepared samples were stored at -70°C until testing. 
4.2.4 The peR 
B1 and P30 PCR was carried out as described in 2.2.9 - 2.2.1l. 
4.2.5 Electrophoresis and Southern Blotting 
PCR products were analysed on 1-1.5% agarose and then blotted as described in 2.2.14-
2.2.18. 
4.2.6 Statistical Analysis 
Statistics were carried out as described in 3.2.6. 
4.3 RESULTS 
4.3.1 Initial comparison of Blood Preparation Methods 
The comparison of DNA extraction methods as a basis for the PCR, using samples from 
patients is shown in Table 4.l. All methods were used successfully in a PCR to amplify 
T gondii DNA from at least one sample. Parasite DNA was detected in four WBC, three 
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WB, five Nucleon and one boiled blood preparations from patients with clinical 
toxoplasmosis. In patients with latent infection parasite was detected in one WBC 
preparation and in one Nucleon preparation, and in sample 6 which was negative on 
repeat testing. Overall the Nucleon system was the most sensitive system with the 
samples tested. However, of the ten antibody negative patients investigated three were 
positive using Nucleon. These samples were negative by all other methods, and as there 
were no signs of toxoplasmosis, these were considered to be false positive results. 
The problem with false positive results in the case of the Nucleon system, and false 
negative results with boiled blood preparations led to the discontinuation of these 
methods in the remainder of this study. 
4.3.2 Detection of Parasite in Samples from HIV Positive Patients 
Table 4.2 shows the number of patients studied in each group. Although 31 patients 
were investigated in Group 1, only 22 attended regularly for follow-up. A similar 
situation occurred in Group 2, where only 26 out of 51 patients investigated .were 
available for follow-up. 
The number and types of samples obtained can be seen in Table 4.3. A total of 221 
blood, 19 CSF, 95 urine and five 'other' samples were available for investigation. 
Group 1 
A total of 104 samples from 22 fu. patients with antibody to T. gondii were tested. The 
majority of these were negative by Bl and P30 PCR, with the exception of samples from 
six patients (see Table 4.4). None of these patients had clinical signs of toxoplasmosis. 
Group 2 
A total of 193 samples were investigated, 142 of which were from the 26 patients 
followed up in the study. These patients who were T. gondii antibody negative, were 
found to be PCR negative with only two exceptions. Of the two, one patient had 
CHAPTER 4 72 
Table 4.1 The peR results using different blood preparation methods 
Sample Status PCR WBC WB Nucleon Boiled 
1 Clinical Bl + - + -
P30 - - - -
2 Clinical Bl - + + + 
P30 - + + -
3 Clinical Bl + - - -
P30 + - - -
4 Clinical Bl - + + -
P30 + - - -
5 Clinical Bl - + + -
P30 - + - -
6 IgG+ Bl - - +/- -
P30 - - +/- -
7 IgG+ Bl - - - -
P30 - - - -
8 IgG+ Bl - - - -
P30 - - - -
9 IgG+ Bl - - + -
P30 - - - -
10 IgG+ Bl + - - -
P30 - - - -
11 IgG - Bl - - + -
P30 - - + -
12 IgG - Bl - - - -
P30 - - - -
13 IgG- Bl - - - -
P30 - - - -
14 IgG - Bl - - - -
P30 
- - - -
15 IgG - Bl - - - -
P30 - - - -
16 IgG- Bl - - + -
P30 - - + -
17 IgG - Bl - - + -
P30 
- - - -
18 IgG- Bl 
- - - -
P30 - - - -
19 IgG - Bl - - - -
P30 
- - - -
20 IgG - Bl - - - -
P30 
- - - -
------------------------------------------------
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Table 4.2 HIV positive patients investigated, showing numbers in each group followed, and 
mean follow-up (f.u.) times. 
73 
Group Status No. Tested No. followed-up Mean time off.u. 
1 T. gondii Positive 31 22 3.9 months 
2 T. gondii Negative 51 26 8.7 months 
3 Clinical toxoplasmosis 10 10 10.7 months 
Total 92 58 7.8 months 
Table 4.3 Samples obtained from the 58 HIV positive patients who were followed-up 
prospectively. 
Samples 
Group Status Blood Urine CSF Other 
1 T. gondii Positive 53 45 5 1 
2 T. gondii Negative 107 25 9 1 
3 Clinical toxoplasmosis 61 25 5 3 
Total 221 95 19 5 
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Table 4.4 Samples from Group 1 patients which were PCR positive 
Patient Month fu Sample Bl P30 
1 1 WBC - + 
2 WBC - + 
2 1 Urine + -
3 3 WB - + 
4 2 WBC + -
2 Urine + -
5 WB + -
5 10 WBC - + 
10 WB + -
6 3 WBC + -
3 WB + -
primary toxoplasmosis and so was transferred to group 3 (patient 10), and the other had 
been tested for antibody at an advanced stage of AIDS, by which time it may have 
been undetectable. A sample taken five years earlier was located and found to be 
antibody positive. In this case, samples of CSF (Bl and P30), WBC (P30) and WB 
(P30) were positive. MRI revealed atrophy of the brain, but no lesions, and CSF 
contained high levels of protein. 
Group 3 
PCR results from the 10 patients in group three with clinical signs of toxoplasmosis can 
be seen in Table 4.5. The mean CD4+ cell count of this group was 8 mm-3. PCR detected 
parasite in blood samples in 11 of 13 episodes of toxoplasmosis. Several patients 
suffered from repeated recrudescence for example in patients 2, 3 and 9. In three cases 
(patients 2, 3 and 10), parasite was detected in blood samples up to four weeks prior to 
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clinical signs of infection. An example of progressive infection can be seen in Table 4.6 
(patient 2). 
Urine samples were positive in patients 3 and 8. These were positive at advanced stages 
of toxoplasmosis, often after symptoms had been controlled. 
Only one of the five CSF samples tested was positive by PCR (patient 2), even though 
they were all obtained during clinical toxoplasmosis. 
Brain biopsy was carried out on two patients (1 and 5) and these were both positive. 
Blood from patient 1 was also PCR positive, however no other samples were available 
at this time from patient 5. 
Patient 9 was an infant with an apparent primary infection. Both parents were T. gondii 
IgG negative and mv positive. MRI revealed lesions and blood samples were PCR 
positive, which confirmed the diagnosis. The patient improved clinically when treatment 
commenced. However as the treatment was reduced, recurrence of symptoms occurred 
and T. gondii DNA was again detected by the PCR in blood samples. Patient 10 was 
originally T. gondii antibody negative, but was found to have primary toxoplasmosis. 
Throughout this period there was no evidence of IgG or IgM, however response to 
treatment was good. 
T. gondii DNA was not detected in blood, urine or CSF from patient 4, although PM 
samples tested were positive by the PCR. This case will be discussed later (4.4). 
Table 4.7 shows the success rate of Bl and P30 PCR in the detection of parasite in 
samples from patients in group 3 who had confirmed toxoplasmosis. In the 19 samples 
tested, B 1 PCR using WB preparations detected 63.2% of positive samples, and 47.1 % 
using WBC preparations. P30 detected 47.4% of WB samples, and 4l.2% of WBC 
samples. These were not statistically different (p=O.581). 
PATIENT SEX AGE CLINICAL DETAILS CD4 TOXOIgG PCR BLOOD WBC URINE CSF E TISSU ~ n 
1 (IDU) M 36 Confusion, haemiparesis 0 + Bl + 
-
0 0 + 
CT scan abnonnal + P30 + 
-
0 0 + 
2 (IDU) M 28 Painful swallowing 3 + Bl + + 
-
0 0 
Episode 1 1{RJscanabnonnal++ P30 + + - 0 0 
Episode 2 Fit 4 Bl + 
- -
+ 0 
P30 + 
- - -
0 
= ~ C'" ;-
"'" ill ~ 
! Cl) ~ J 
~ 
~ g g, tIl 
3 (HO) M 33 (2 prior episodes) Convulsions 9 + Bl + 
-
0 
-
0 
Vi' n 
-e: 
Episode 3 CT scan nonnal P30 + 
-
0 
-
0 et 
0-
Episode 4 Convulsions 3 Bl 
-
+ + 0 0 ~, 
-1{RJscanabnonnal++ P30 
-
+ + 0 0 
4 (Bi) M 45 (1 prior episode) 10 + Bl 
- - - -
+ 
tIl 
8-
"1:1 
Episode 2 1{RJscanabnonnal+ P30 
- - - -
+ n ~ 
5 (Ho) M 41 (1 prior episode) 4 + Bl 0 0 0 0 + Cil tIl 
s:: 
Episode 2 P30 0 0 0 0 + ii 
6 (IDU) M 30 Deafness, nephritis 14 + Bl + + 0 0 0 
hypertension P30 
-
+ 0 0 0 
7 (IDU) M 32 Ataxia 10 + Bl + + + 0 0 
Vomiting P30 + + + 0 0 
~ 
3 
"0 
~, 
(1) 
~ 
ei' 
8 (HET) M 65 1{RJ scan abnonnal + 8 + Bl + 
-
0 0 0 
CVA P30 
-
+ 0 0 0 ~ s:: 
"0 
9 (VER) F 9112 Fits NA - Bl + + 0 - 0 
Episode 1 1{RJ scan abnonnal + P30 
- -
0 - 0 
w 
~, g. 
Episode 2 Treatment reduced Bl + 0 0 0 0 
Encephalitis P30 + 0 0 0 0 
10 (IDU) F 31 MR1 scan abnormal ++ 0 
-
Bl + + 0 0 0 
P30 + 
-
0 0 0 
- ------------------------------------------------------------------------------------------------------------------~ 
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Table 4.6 Recrudescence in patient 2 (Group 3). 
Date Sample Bl P30 CD4 Clinical Data 
3/93 WBC - - 9 Treatment: Dapsone. 
WB - -
Urine - -
4/93 WBC + + 3 Episode 1 
WB - + Cerebral mass lesions 
5/93 Urine - - 4 Lesions reduced 
Urine - -
6/93 WBC - -
WB + -
8/93 CSF + - Episode 2 
WBC - - Treatment: Pyrimethamine 
WB + + and Sulphadiazine 
8/93 WBC - -
WB - -
Urine - -
9/93 WBC - -
WB - + 
10/93 WB - -
10/93 WBC - -
WB - -
Table 4.7 Positivity rates of the HI and P30 PCR in WBC and WB preparations 
Blood Preparation Method 
PCR WBC WB 
Bl 8/17* (47.1%) 12/19 (63.2%) 
P30 7/17* (41.2%) 9/19 (47.4%) 
* Two samples were insufficient for WBC preparation. 
------------------------------------------- --
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Table 4.8 PCR results from PM samples from T gondii antibody positive patients 
Sample No. tested HI PCR Positive P30 PCR positive 
CSF 3 1 0 
Brain 8 4 4 
Spinal cord 7 4 4 
Lymph node 6 1 2 
Thymus 6 2 2 
Liver 6 1 0 
Lung 5 1 0 
Bone marrow 6 1 1 
Adrenal 6 1 0 
Spleen 6 1 0 
Colon 6 1 0 
Kidney 7 0 0 
Myocardium 5 2 3 
Pancreas 3 1 0 
Rectal muscle 3 1 1 
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Post Mortem Study 
PM samples were obtained from ten patients, eight which were antibody positive, and 
two which were antibody negative. Three of the PM's were small, containing only brain 
and spinal cord, however most included up to IS tissues i.e. brain, spinal cord, adrenal, 
thymus, myocardium, diaphragm, lung, kidney, liver, pancreas, colon and rectal muscle. 
A total of 19 samples were tested from the two T. gondii antibody negative patients, one 
of whom had been followed in group 2. All of these were BI and P30 PCR negative. 
Of the eight T. gondii antibody positive PM's, one containing only three samples was 
PCR negative. The remaining seven had at least one tissue which was PCR positive. A 
summary of PM results is presented in Table 4.8. Samples (n=lS) obtained at PM 
examination from patient 4 (see Table 4.S) in group 3, who suffered from clinical 
toxoplasmosis, were tested. Although samples collected at the time of illness were 
negative by PCR, 14 PM samples were positive by the B 1 PCR, and seven were positive 
byP30PCR. 
4.3.3 Detection of Parasite in Samples from RIV Negative Patients 
Eight patients with suspected toxoplasmosis were investigated. Fifteen blood, six urine, 
three CSF and placenta, amniotic fluid, cord blood and skin biopsy samples were 
available. Five of the patients were T. gondii positive by PCR (patients 3, 4, S, 6 and 8) 
in a wide variety of samples which are outlined in Table 4.9. Patient 1, with leukaemia 
was tested in order to exclude toxoplasmosis as a cause of symptoms. Patient 2 
accidentally inoculated himself with live parasite during an experimental procedure. He 
was treated immediately and blood taken at the time was PCR negative and T. gondii 
antibody positive, showing signs of previous infection. Patient 3 contracted primary 
toxoplasmosis during the last trimester of pregnancy. Blood was found to be PCR 
positive at this time and the patient was given standard treatment. Samples of blood, 
amniotic fluid, placenta and cord blood were also found to be positive at delivery. The 
infant appeared to be normal at this stage, and also when examined several months later. 
Patient 4, who was T. gondii antibody positive became ill several months after receiving 
a kidney transplant. She responded to treatment and remains well, although one blood 
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sample taken three months later was still positive by the PCR. Patient 5 was in a high 
risk group because of intravenous drug use. He was found to have a primary infection 
and samples remained PCR positive over three months. Three patients were not 
immunocompromised, but toxoplasmosis was suspected on the grounds of 
lymphadenopathy (patients 6, 7 and 8). Two of these were primary infections, with 
samples remaining positive by the PCR for four months for patient 6 and two months for 
patient 8. 
Table 4.9 PCR results using samples from lllV negative patients with suspected 
toxoplasmosis. 
Patient PCR WBC WB Urine CSF Other 
1) Leukaemic Bl - - 0 - 0 
P30 - - 0 - 0 
2) Needlestick Bl - - 0 0 0 
P30 - - 0 0 0 
3) Pregnant Bl + + 0 0 Amniotic fluid, cord 
P30 + + 0 0 blood & Placenta + 
4) Transplant Bl + - 0 - 0 
P30 + - 0 - 0 
5) IVDU Bl - + + 0 0 
P30 - + - 0 0 
6) Child (4 yr) Bl + + 0 0 0 
P30 + + 0 0 0 
7) Child (10 yr) Bl 0 - 0 - 0 
P30 0 - 0 - 0 
8) Female Bl + - + 0 Skin biopsy -
P30 - - + 0 
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4.4 DISCUSSION 
Initial work on the preparation of blood samples for use in PCR demonstrated that the 
simple technique of boiling samples in water was insensitive, and revealed that the more 
complex Nucleon system was prone to contamination problems. The problem with the 
latter was due to the number of steps involved, each of which increased the chance of 
contamination with T. gondii DNA, even though the number of steps was less than in a 
traditional DNA extraction (2.2.3). The method found to be the most useful for the 
detection of parasite was proteinase K digestion which is a compromise between the 
simple boiling method, which may not break down cellular material sufficiently to release 
DNA, and the Nucleon system. Proteinase K was also found to be more efficient than the 
boiling system in the preparation of experimental mock samples (GroB et al. 1992). 
The preparation of other samples such as tissue and CSF became more documented 
during the course of this study (Lebech et al. 1992, Gozlan et al. 1992) and so 
comparison of different methods was not carried out. However, because of indications of 
the inhibitory effects of cellular debris (Grover et al. 1990), a small amount of starting 
material was used in tissue preparation and this was standardised at 0.2 g throughout the 
study. 
In AIDS patients, blood samples were found to be useful in the diagnosis of 
toxoplasmosis, often before clinical systems were apparent. Whole blood preparations 
were more sensitive than WBC preparations, however similar results were not obtained 
from immunocompetent patients. There may be two explanations for this; one possibility 
is that the majority of parasite is present in whole blood samples, and not in the WBC 
fraction (Hitt and Fillice 1992); secondly, in an immunocompetent individual a large 
number of cells can be obtained from the buffy coat, and therefore a small number of 
parasites can be detected. In AIDS patients where the WBC count is severely reduced 
(see Table 4.5) it is often difficult to see any band in the layer over the Lymphoprep. 
Therefore most parasite may be lost to the red blood cell (RBC) layer, and not detected 
by the PCR. 
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It was also possible to detect parasite from urine samples, but these were generally 
positive later than blood samples, and often after illness had subsided. This may have 
been due to the detection of DNA from non-viable parasites which had been broken 
down by therapeutic agents or the immune system, and were being cleared by the kidney. 
This suggests that these samples are of little practical use in a diagnostic setting. 
Parasite was detected in both brain biopsy samples obtained. No other samples were 
available at this time from one of these patients (patient 4), and PCR along with l\1RI and 
clinical findings produced a diagnosis. However blood samples from the other patient 
were positive. If blood had been taken initially, a positive PCR result would have made 
the invasive procedure unnecessary. 
The combination of placenta and amniotic fluid was useful in the diagnosis of congenital 
toxoplasmosis. Only two ocular samples were obtained which were negative, and so it is 
not possible to speculate how useful these samples may be in the diagnosis of ocular T. 
gondii infection. 
Disappointingly, CSF proved to be unhelpful in the diagnosis of toxoplasmosis, with only 
one positive PCR result. This was not due to inhibitory factors in most cases, as few of 
these samples prevented amplification in control reactions carried out alongside the test. 
Parasite was detected in blood, often before illness, which suggests that recrudescence is 
not merely a localised event in the brain, but that parasite is also transported via the 
blood to target organs. Therefore testing blood samples by the PCR is useful in the 
diagnosis of infection in patients where more traditional serological techniques are 
inadequate. These include AIDS patients, transplant patients, pregnant women and their 
new-born infants as demonstrated in this study. In these cases serology would have 
limited applications because of maternal antibody in the case of congenital 
toxoplasmosis, and the prior existence of antibody in the transplant patient. 
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There are some limitations associated with the PCR in the diagnosis of toxoplasmosis in 
AIDS patients. Parasite was found circulating in 27.2% of T. gondii antibody positive 
patients on at least one occasion during this study. These patients showed no clinical 
signs of toxoplasmosis, which may mean that the system detected the sporadic 
breakdown of tissue cysts. The mean CD4+ cell count among these individuals was 46 
mm-3, which was higher than those with clinical toxoplasmosis with a mean of 8 mm-3. It 
is difficult to assess whether there were no clinical indications in these cases because the 
individuals still had some immunological capacity to destroy parasite released from the 
sporadic breakdown of cysts and so prevent recrudescence, or because of some other 
genetic factor. This was suggested by McLeod et aL (1989), and Suzuki et al. (1991) as 
a reason for the ability of certain strains of mice to prevent infection. 
Parasite was detected in samples from seven out of eight PM's from antibody positive 
patients, but only 50% of CNS samples (such as brain and spinal cord) were found to 
contain parasite. In comparison the CNS was involved in all ten cases of recrudescence 
in group 3. As the PCR can detect tissue cysts, these could not be present in large 
numbers in patients with chronic infection as they were not always detected. This 
suggests that parasite can invade the CNS from other sources to some extent during 
reactivation. Therefore blood may transport the parasite to the brain and be responsible 
for many, but not necessarily all, cases of recrudescence. One PM was from a patient 
with clinical toxoplasmosis from which strong positive results were obtained from most 
tissues (14 out of 15). However with this PCR system it is impossible to differentiate 
active infection from the detection of latent tissue cysts. 
In conclusion, the success of blood as a sample in which to detect parasite makes 
invasive techniques such as brain biopsy and lumbar puncture unnecessary. However not 
all cases of recrudescence were detected by PCR in these samples. The timing of sample 
collection is therefore believed to be critical to successful diagnosis. Results should be 
taken into consideration with clinical and MRI details. There is therefore a need to 
further investigate parasite / host interaction. 
CHAPTER 5 
The Development of an Animal Model of Recrudescence of T. gondii 
Infection 
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5.1 INTRODUCTION 
The incidence of recrudescence of toxoplasmosis in AIDS patients with evidence of past 
infection is reported to be 33% (Luft and Remington 1992). Therefore many of these 
patients are at risk in countries such as France where 80% of individuals have IgG 
against T gondii (Wanke et at. 1987). 
'In the patient study (chapter 4), 15% of the Edinburgh AIDS cohort was found to have 
antibody to T gondii. Parasite was detected by the PCR in peripheral blood, often before 
clinical manifestations in these patients. This suggests that a parasitaemia is involved in 
reactivation although it may be transient. However parasite was detected in six AIDS 
patients with T gondii IgG (Group 1), where there were no clinical signs of reactivation. 
The aim of this study was to develop an animal model of recrudescence to investigate the 
significance of parasitaemia in patients at risk. This may provide information on the 
incidence of parasitaemia, and its relevance as an indicator in recrudescence from latent 
to acute infection. The number of animals affected by recrudescence could be monitored 
and various samples investigated for evidence of infection. 
A limited amount of work has been carried out using animals to investigate parasite / 
host interaction during acute infection (Conley and 1 enkins 1981, F erguson and 
Hutchison 1987). Studies involving the use of immunocompromised mice include the use 
of nude mice by Lindberg and Frenkel (1977). Results revealed that nude mice died 6.3 
days post infection, unless they received transplanted thymic cells. However the need for 
a good animal model to investigate new drug therapies was highlighted by 10hnson 
(1992). This must therefore involve animals with recrudescence of a chronic infection. 
Lymphodeficient SCID mice were used by 10hnson (1992) to investigate chronic 
infection, however both nude and SCID mice are difficult to work with because of their 
severely impaired immune systems, and require isolation units and sterile conditions. To 
avoid these complications the method chosen for this study was similar to that described 
by Powles et al. (1992) where immunosuppression and Pneumocystis carinii infection 
resulted from the addition of dexamethasone to the animals' drinking water. This would 
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enable the establishment of a chronic T. gondii infection in mice prior to dexamethasone 
treatment and therefore mimic the situation in AIDS patients where a chronic infection is 
established prior to immunosuppression. 
5.2 PRELIMINARY INVESTIGATIONS 
5.2.1 Pilot study 
A pilot study was carried out to investigate recrudescence in chronically infected mice 
treated with dexamethasone with the aim of mimicking reactivation of infection in the 
immunocompromised human host. If successful, this animal model would be a valuable 
tool in studying the mechanisms involved in the switch from latent to active infection. 
Experimental Design 
Porton mice were chronically infected following i.p. inoculation with 30 T. gondii tissue 
cysts of the M3 isolate (groups 1 - 3). Groups 4 - 6 consisted of Toxoplasma negative 
mice. Details of treatment protocol is shown in Table 5.1. 
Table 5.1 Treatment protocol during the pilot study 
Group no. Toxoplasma status Dexamethasone level 
1 9 Chronic Infection 8 mg 1-1 
2 9 Chronic Infection 4mgl-1 
3 10 Chronic Infection nil 
4 10 Negative 8mgl-1 
5 9 Negative nil 
6 10 Negative 8 mg 1-1 + Tetracycline (1 g 1-1 ) 
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Six weeks after the initial infection dexamethasone was administered in the drinking 
water of the appropriate groups which was then changed every two days. Blood samples 
were taken by tail bleed before immunosuppression treatment commenced, and weekly 
thereafter. Mice were monitored daily over eight weeks, and animals which showed signs 
of illness were culled using excess CO2 . Samples of brain, blood and heart were taken for 
PCR analysis. Signs of illness included limited "clockwork" mobility, and a hunched 
appearance alongside evidence of emaciation and dehydration. At the end of the eight 
week study period all remaining mice were culled and examined as above. All samples 
were examined using the B 1 PCR. 
Results 
At the higher level of dexamethasone treatment (Group 1) 6/9 mice showed signs of 
recrudescence within the eight week test period. In comparison, only 3/9 mice on low 
level dexamethasone treatment (Group 2) became ill due to reactivation of infection. 
None of the chronically infected mice in group 3 which did not receive dexamethasone 
treatment showed any sign of illness. This was also the case with mice from Groups 4, 5 
and 6, where none of the samples tested were PCR positive. However some mice 
negative for Toxoplasma (Group 4) became ill due to infection from unrelated 
opportunistic organisms. This problem was eliminated by Tetracycline administered at 
levels of 1 g 1-1 in drinking water (Group 6). 
The pilot study indicated that dexamethasone was appropriate in the development of a 
mouse model of T. gondii recrudescence. Therefore the study was repeated with the 
inclusion of pathological and serological investigations which could reveal useful 
information on the recrudescence of Toxoplasma in the immunocompromised host. This 
study may indicate whether the PCR detected the presence of tachyzoites (which indicate 
an active infection), or merely detected sporadic tissue cysts, or products from their 
breakdown. Serological testing and pathological examination may also be of value in 
recording how antibody levels and parasite recrudescence vary with immunosuppressive 
therapy. 
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5.3 MATERIALS AND METHODS 
5.3.1 Treatment Protocol 
A pool of 108 chronically infected Porton mice was established (54 females and 54 
males), and a further 50 naive Porton mice (25 females and 25 males) were also included 
as control groups. Data from the pilot study indicated that to observe differences 
between treatments at the 5% significance level it was necessary to include 20 mice in 
each group. Details of the treatment protocol can be seen in Table 5.2. All groups which 
received dexamethasone also received 1 mg 1-1 tetracycline in drinking water for the 
duration of the study. In addition to the 100 mice used in this part of the study, a further 
two from Groups 1 to 3 were used each week to monitor the progression of infection in 
chronically infected mice (16 per group over eight weeks). In Group 4, a Toxoplasma 
negative control, only one animal was tested weekly. These were sequentially culled and 
tested for evidence of recrudescence. 
Table 5.2 Treatment protocol 
Group Toxoplasma status Dexamethasone No. for main No. for sequential 
level study testing 
1 Chronic Infection 8mgl-1 20 16 
2 Chronic Infection 4mgl-1 20 16 
3 Chronic Infection nil 20 16 
4 Negative 8 mg I-I 20 8 
5 Negative nil 20 2 
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5.3.2 Investigations 
Mice were observed daily, and samples of blood, brain and heart were collected from 
culled mice as described in the pilot study (5.2.1). The rate of recrudescence was 
assessed by the number of mice showing signs of illness which were culled and 
investigated. 
peR Analysis 
The B 1 PCR was used to examine samples of blood, brain and heart obtained at PM 
examination, and also weekly blood samples. 
Pathology 
Brain samples were obtained from all mice at PM examination and were fixed in 10% 
formal saline before embedding in paraffin wax. Four 5 Ilm sections were cut and stained 
with HE then examined for evidence necrosis, gliosis and lymphoid inflammation. 
Sections in which no evidence of change was found were scored (-); sections with 
minimal to mild presence of change was found were scored (+); and those with moderate 
to severe change were scored (++). (Work carried out by S. Maley and D. Buxton). 
Serology 
Plasma samples were tested for IgG against T. gondii using the ELISA (Buxton et al. 
1988) on day 0, and then again at PM examination (work carried out by S. Maley). 
Statistical AnalYSis 
Statistical analysis was performed on the effect of dexamethasone on the presence or 
absence of the parasite in samples, and also on the mortality rate in the different 
treatment groups. Analysis was carried out using Fischer's Exact test which is unaffected 
by low or zero counts. 
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5.4 RESULTS 
5.4.1 Level of Recrudescence 
The results of the B 1 PCR using samples of blood, brain and heart can be seen in Table 
5.3. The mortality rate was 36.4% (8 out of 22) in Group 1, 10% (2 out of 20) in Group 
2, and 0% in Group 3. One animal died in Group 4, but this was accounted for by the 
occasional loss of animals in any given group. This animal had no symptoms suggestive 
of toxoplasmosis, but unfortunately no samples were available for testing because most 
of the animal had been consumed by other members of the group. Statistical analysis 
revealed that the mortality rate of animals in Group 1 was significantly higher than that 
of Group 3 (p=0.0027), and of borderline significance when compared to Group 2 
(p=0.0485). The mortality rate in Group 2 was not significantly higher than Group 3 
(p=0.2436). 
In the 10 mice from Groups 1 and 2 which showed signs of recrudescence, parasite was 
detected in 9 brain samples, 6 heart samples, and 3 blood samples (only 8 were available 
for testing). 
5.4.2 Weekly Blood Samples 
The results of the B 1 PCR analysis of the weekly blood samples are shown as 
percentages in Table 5.4 as numbers decreased with time. Samples were positive in 
38.9% (49 out of 126) samples from Group 1, 23.4% (32 out of 137) samples from 
Group 2, and 8.6% (12 out of 140) samples in Group 3. These results were highly 
significant: Group 1 against Group 2 (p=0.0064); Group 1 against Group 3 (p<O.OOOI); 
Group 2 against Group 3 (p=0.008). All samples from Groups 4 and 5 were negative. 
5.4.3 Sequential Culls 
None of the samples obtained from Groups 4 and 5 was positive by the B 1 peR (see 
Table 5.5). In contrast, most brain samples were positive in Groups 1 to 3, with no 
difference between treatment regimes. None of the blood samples was PCR positive in 
Group 3, whereas 3 out of 10 were positive in Group 2, and 6 out of 10 were positive in . 
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Table 5.3 The B1 peR results using samples from mice showing signs of recrudescence 
Group 014 015 
1 BI+ 
T+8mg Br+ 
H+ 
2 BI 0 
T+4mg Br + 
H + 
3 
T+Omg 
4 
T- 8mg 
5 
T-Omg 
o -No sample available 
BI- Blood 
Br - Brain 
H - Heart 
017 018 019 
BI- BIO BI + 
Br+ Br+ Br+ 
H+ H - H -
020 021 031 032 034 038 
BI- BI+ BI- BI-
Br+ Br- Br+ Br+ 
H - H+ H+ H+ 
BI -
Br + 
H -
BI 0 
Br 0 
H 0 
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LOST 
36.4% 
10% 
0% 
5% 
0% 
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Table 5.4 Numbers of weekly blood samples which were positive by the Bl peR (shown as a 
percentage because of reducing numbers). 
Group I Treatment DO D7 D14 D21 D28 D35 D42 MEAN 
Gl (T+ 8 mg) 10 30 55 35 43 72 33 38.9 
(-5) (-1) (-2) 
G2 (T+ 4 mg) 5 30 25 20 30 27 27 23.4 
(-1) 
G3 (T+ 0 mg) 0 15 10 5 10 10 10 8.6 
G4 (T- 8 mg) 0 0 0 0 0 0 0 0 
(-1) 
G5 (T- 0 mg) 0 0 0 0 0 0 0 0 
(Numbers in brackets refer to mice lost during the preceding week) 
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Group 1. Group 1 was significant against Group 3 (p=0.0054), but not against Group 2 
(p=0.1849). Heart samples were positive by the PCR in 7 out of 10 cases in Groups 1 
and 2, and in only lout of 10 cases in Group 3, which was significantly different (Group 
1 against Group 3, and Group 2 against Group 3 p=0.0099). 
5.4.4 Final Culls 
The results of the B 1 PCR using samples from PM examination at the final cull is 
presented in Table 5.6. Blood was positive by the Bl PCR in 5 out of 14 (35.7%) 
samples from Group 1, 5 out of 18 (27.7%) in Group 2, and 3 out of20 (15%) in Group 
3. These results were not significantly different. All brain samples were positive in Group 
1, compared with 17 out of 18 (94.4%) in Group 2, and 15 out of20 (75%) in Group 3. 
These results were not significantly different. A similar result was obtained with heart 
samples which were positive in all 14 samples in Group 1, 15 out of 18 (83.3%) in 
Group 2, and 9 out of 20 (45%) in Group 3. There was a significant difference between 
Groups 1 and 3 (p=0.0006). 
5.4.5 Pathology 
Haematoxylin / eOSIn staining of brain sections demonstrated the effects of 
dexamethasone on necrosis, gliosis and lymphoid inflammation, in treated and control 
animals (see Table 5.7 and Figures 5.1 to 5.4). 
Necrosis 
Dexamethasone increased the level of necrosis in Groups 1 and 2, especially in mice 
showing clinical signs of illness (Figure 5.3). The level of necrosis was low in apparently 
well animals when compared to those that were ill (Table 5.7b). 
Gliosis 
The effect of dexamethasone was to reduce the incidence of gliosis in most animals. 
However gliosis was present in mice which were ill when compared to those which were 
well (Figure 5.2) (Table 5.7b). 
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Table 5.5 The Bl peR results from PM examination ofsequentially culled mice. 
Group Sample Positive Negative 
Base Line Blood 0 2 
T. gondii IgG positive Brain 2 0 
(day 0) (n=2) Heart 1 1 
Group 1 Blood 6 4 
(n=lO) Brain 9 1 
Heart 7 3 
Group 2 Blood 3 7 
(n=10) Brain 9 1 
Heart 7 3 
Group 3 Blood 0 10 
(n=10) Brain 9 1 
Heart 1 9 
Group 4 Blood 0 5 
(n=5) Brain 0 5 
Heart 0 5 
Group 5 Blood 0 2 
(n=2) Brain 0 2 
Heart 0 2 
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Table 5.6 The B1 peR results from samples taken at PM examination at the final cull. 
Group Sample Positive Negative 
1 Blood 5 9 
(n=14) Brain 14 0 
Heart 14 0 
2 Blood 5 13 
(n=18) Brain 17 1 
Heart 15 3 
3 Blood 3 17 
(n=20) Brain 15 5 
Heart 9 11 
4 Blood 0 20 
(n=20) Brain 0 20 
Heart 0 20 
5 Blood 0 10 
(n=lO) Brain 0 10 
Heart 0 10 
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Table 5.7a Results (%) of pathological examination of brain sections (total numbers). 
Necrosis Gliosis Lymphoid Inflammation 
Group - + ++ - + ++ - + ++ 
1 (n=32) 84 13 3 41 50 9 9.5 87 3.5 
2 (n=31) 97 0 3 39 55 6 9 75 16 
3 (n=30) 100 0 0 23 67 10 0 70 30 
4 (n=25) 100 0 0 100 0 0 100 0 0 
5 (n=10) 100 0 0 100 0 0 100 0 0 
Table 5.7b Results (%) of pathological examination of brain sections. Numbers in brackets refer 
to those mice showing clinical signs of illness in Groups 1 and 2. 
Necrosis Gliosis Lymphoid Inflammation 
Group - + ++ - + ++ - + ++ 
1 n=24 92 8 0 46 46 8 12.5 87.5 0 
(n=8) (57) (33) (10) (20) (70) (10) (0) (90) (10) 
2 n=29 100 0 0 41.5 55 3.5 10 76 14 
(n=2) (50) (0) (50) (0) (50) (50) (0) (50) (50) 
3 n=30 100 0 0 23 67 10 0 70 30 
4n=25 100 0 0 100 0 0 100 0 0 
5 n=lO 100 0 0 100 0 0 100 0 0 
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Figure 5.1 Lymphoid meningitis in the median sulcus of the cerebrum. 
Cage 4 (T+ 4 mg 1-1) 
Mouse 1 
HE staining 
xlO 
Photograph by D. Buxton 
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Figure 5.2 Focal gliosis and mild lymphoid perivascular cuffing adjacent to the 
hippocampus 
Cage 4 (T+ 4 mg 1"1) 
Mouse 1 
HE staining 
xlO 
Photograph by D. Buxton 
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Figure 5.3 Acute necrosis and numerous T. gondii tissues cysts in the cerebral cortex. 
Mouse 8 
HE staining 
xlO 
Photograph by D. Buxton 
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Figure 5.4 Two T gondii tissue cysts with a small associated glial focus . 
Cage 5 (T+ nil mg 1-1) 
Mouse 6 
Immunoperoxidase staining 
x20 
Photograph by D. Buxton 
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Lymphoid Inflammation 
The incidence of lymphoid inflammation was reduced with dexamethasone treatment 
when the total number of mice was observed. Again, when levels were compared 
between sick mice and well mice, the level of lymphoid inflammation was higher in those 
which were ill (Table S.7b). 
5.4.6 Serology 
Results of the IgG ELISA on the blood samples obtained at day ° were compared with 
those obtained at PM examination (see Table 5.8). At day 0, all samples from mice in 
Groups 1 to 3 were positive, with similar OD values. Samples from mice in Groups 4 
and 5 were negative. Samples from Groups 1 to 3 remained positive after treatment, 
however the mean OD value dropped from 121.5 to 99.5 in Group 1. 
Table 5.8 IgG ELISA results from mice on day 0 and day 42. 
Group No. tested OD. Value No. tested OD. Value 
(day 0) (Day 42) 
1 12 121.5 14 99.5 
2 12 119.7 18 119.7 
3 12 128.6 20 126.7 
4 8 10* 20 10* 
5 8 10* 10 10* 
*Cut off = 25 
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5.5 DISCUSSION 
Previous studies of T. gondii infection in animals have revealed a lot about parasite / host 
interaction. However many areas such as CNS involvement remain unclear. Tissue cysts 
in the brain remain within intact neurones which explains the absence of an inflammatory 
response (Ferguson and Hutchison 1987), but this differs from the cases of 
recrudescence in this study where an inflammatory response was seen in sick animals 
(5.4.5). A similar response was documented by Vollmer et al. (1987) where neurologic 
symptoms were present alongside symptoms of dehydration and emaciation. 
Results in a study by Johnson (1992) using SCID mice revealed that CD4+ CD8+ T cells 
are crucial to the development of immunity in the host. However despite a deficiency of 
T and B lymphocytes, SCID mice probably possess another mechanism of temporary 
resistance to active T. gondii which is gamma interferon-dependent. This did not protect 
animals for long as they all succumbed to infection within a short time (mean of 6.3 
days). The use of SCID mice and mono clonal antibody was rather artificial when 
compared to recrudescence in the AIDS population where only 30 - 35% of individuals 
with chronic infection show signs of infection. Although Johnson (1992) suggests that 
drugs such as cortisone may be non-specific, drug therapy based on the methods of 
Powles et al. (1992) was chosen for this study to better mimic the effects seen in the 
AIDS population. 
5.5.1 The Use of Dexamethasone to Create an Animal Model of T. gondii 
Recrudescence 
Dexamethasone was successfully used to create a mouse model of Pneumocystis carinii 
infection (powles et al. 1992). The application of dexamethasone resulted in an increased 
mortality rate in chronically infected mice, especially at the high dose rate of 8 mg ml-1 
(Group 1). These animals exhibited classic locomotor signs of toxoplasmosis which were 
not observed in any of the control groups. There were no differences in the detection of 
parasite in samples of blood and brain in Groups 1, 2, and 3, but heart samples were 
positive on a greater number of occasions when compared to untreated mice (Group 3). 
Serological testing also demonstrated a decrease in the OD value the of IgG ELISA in 
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Group 1, indicating that dexamethasone did cause immunosuppression at a high level of 
administration. 
The results of pathological examination of brain sections reveal two effects of 
dexamethasone on the mechanics of infection. Firstly, dexamethasone acts as 
immunosuppressant and therefore causes recrudescence of a chronic infection in a 
number of mice. Secondly, the drug also acts as an anti-inflammatory agent (and is often 
used as such), and so reduced the amount of damage in many cases. Levels of necrosis 
were not influenced by the anti-inflammatory effects of the drug and so the overall result 
was an increase in damage with increased levels of therapy. However the level of gliosis 
and lymphoid inflammation was influenced by anti-inflammatory effects and so reduced 
any pathological symptoms. This was not the case in sick mice where the majority 
showed moderate to severe signs of both gliosis and lymphoid inflammation. 
These results indicate that dexamethasone did cause recrudescence in chronically 
infected mice, and is a useful tool for further investigation of parasite / host interaction. 
However there may be problems due to the anti-inflammatory effects of the drug which 
could influence the level of recrudescence in treated animals. 
5.5.2 The Incidence of Parasitaemia in Recrudescence of T. gondii Infection 
The detection of parasite in the blood of chronically infected mice from day 0 implies 
that parasite does occasionally circulate in the host, as was suggested by Conley and 
Jenkins (1981). In most cases this is cleared by the immune system to prevent 
recrudescence. Immunosuppression resulted in an increase in the number of samples in 
which parasite was detected, however these results were not always associated with 
clinical signs of recrudescence during the course of the study. The samples may be 
positive by the PCR due to intermittent cyst breakdown and the release of small numbers 
of parasite into the blood which are not high enough to cause recrudescence, or be 
inactivated by any remaining defences within the host. This observation is backed up by 
the occurrence of positive samples obtained from chronically infected mice with no 
immunosuppressive therapy (Group 3). 
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5.5.3 The Use of Blood Samples for the Detection of Recrudescence 
As parasite was often detected in mice which remained clinically well, blood samples may 
be of limited value in the diagnosis of recrudescence of chronic infection in the 
immunocompromised host. However they may still be of use when considered alongside 
other sampling and testing protocols. This was also the case in the patient study where 
blood samples were positive by the B 1 PCR in a number of cases (Chapter 4). These 
were unlikely to be false positive results because none of the many negative controls 
used throughout each test were positive, and the control animals remained negative 
throughout the study. A positive result from a blood sample from an individual at risk 
may indicate a high risk of recrudescence in the near future, and suggests the need for 
close monitoring for symptoms of toxoplasmosis. 
Other samples such as heart may be useful in detecting recrudescence as parasite was 
detected in samples from immunosuppressed mice in a significant number of samples. 
Brain samples tended to be positive in most chronically infected mice, whether they 
received immunosuppressive therapy or not. Therefore, although brain biopsy has been 
used to detect many cases of recrudescence, the PCR may be detecting high levels of 
tissue cysts rather than active tachyzoites. In addition, the invasive nature of these 
samples does not readily permit their use in the diagnosis of T. gondii infection. 
In conclusion, dexamethasone was used successfully to cause recrudescence of T. gondii 
infection in chronically infected mice. However blood samples were PCR positive in 
some instances even before immunosuppression therapy began. This would suggest that 
either active parasite was still circulating, or that latent cysts were occasionally breaking 
down releasing parasite into the blood. It would be useful to monitor the mice in such a 
study for a considerable time, certainly for longer than six weeks, in order to discover 
whether animals with parasitaemia did go on to develop toxoplasmosis. The development 
of a quantitative PCR may also be of value in measuring the level of parasitaemia in the 
host, therefore creating a system by which the risk of recrudescence could be 
ascertained. 
CHAPTER 6 
The Development of a Quantitative Polymerase Chain Reaction 
I 
I 
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6.1 INTRODUCTION 
Quantitative PCR (qPCR) may be of value in assessing the relevance of positive T. 
gondii PCR results (Holliman et al. 1990b, Barker and Holliman 1992). Development of 
the qPCR has been problematic due mainly to the exponential nature of the PCR system, 
with small variations in amplification efficiency dramatically affecting product yield 
(Foley et al. 1993). 
Several methods have been attempted for the development of qPCR systems in the study 
of other organisms. Pang et al. (1990) and Kellog et al. (1990) radiolabelled one of the 
oligonucleotides used in amplifying levels of Human Immunodeficiency Virus type I 
(HI V -1). DNA fragments were separated by gel electrophoresis, and the level of 
amplification in an excised band was measured using a scintillation counter. Katz et al. 
(1990) used the co-amplification of mouse "housekeeping" genes in the study of Herpes 
simplex virus in these animals. The mouse gene provided a control for amplification rates 
when the two targets were amplified. Target levels were then compared directly using 
gel electrophoresis, autoradiography or densitometry. Arrigo et al. (1990) used a similar 
method to quantify mv -1. However, this system involved the use of different primers 
and amplification of these fragments was not completely invarient (Foley et al. 1993). 
A target of different size was co-amplified by Wang et al. (1989) which was then 
separated by electrophoresis. The amount of DNA target was extrapolated against a 
standard curve while in the exponential phase. There is however potential for error with 
the PCR using size differences to separate the products, ego the activity of polymerase 
may bias the results over different lengths of product. There is also the possibility of the 
development of secondary structures which may prevent primer annealing and extension. 
The use of an internal control which is identical to the target apart from the existence of 
a restriction site may aleviate the problems encountered with other methods of qPCR 
(Foley et al. 1993). Both the target and control DNA would amplify with the same 
efficiency, as they would compete equally under given conditions. The ratio of products 
will therefore remain constant throughout amplification (Gilliland et al. 1990). The point 
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at which target and control DNA are equal can then be found by direct comparison using 
gel electrophoresis. This was the method chosen for development of a qPCR in this study 
The P30 PCR was chosen as the bases of a qPCR because it amplifies a single copy gene, 
therefore limiting problems associated with multiple copy genes such as B 1 which may 
vary in copy number. A suitable site was chosen for mutagenesis to create a novel 
restriction site by altering two bases. This mutated target could then be used in a single 
P30 PCR with the internal DS38 and DS39 primers (Chapter 2 and Figure 6.1) to 
produce fragments of identical length, but varying in only the two base changes. When a 
series of reactions is carried out containing the same sample input, but varying known 
amounts of mutated DNA, a competitive system will arise where the largest amount of 
input DNA will be amplified preferentially. Fragments may then be separated by 
restriction enzyme analysis, followed by electrophoresis. The point at which the amount 
of undigested product equals the amount of digested product (mutated DNA) identifies 
when input of both fragments is identical. This should reveal the original input of sample 
DNA. 
Specific mutations can be introduced by cloning (Botstein and ShortIe 1985), or by using 
PCR technology (Higuchi et at. 1988, Vallette et al. 1989). The "Altered sites in vitro 
mutagenesis system" (promega) and the PCR using mismatched primers were 
investigated simultaneously with the aim of creating a novel restriction site in the P30 
target DNA. The site chosen for mutation was at 116 (A to C) and 117 bp (G to C) to 
introduce a Smal restriction site which would cut to produce fragments of 118 and 404 
bp (see Figure 6.1). 
The successful development of a qPCR may then be used to further examine T. gondii 
infection in human samples both as a research tool and as a means of monitoring the 
course of illness. 
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Figure 6.1 The mutation site on the P30 gene. 
DS38 
1 CGACAGCCGC GGTCATTCTC ACACCGACGG AGAACCACTT CACTCTCAAG 50 
51 TGCCCTAAAA CAGCGCTCAC AGAGCCTCCC ACTCTTGCGT ACTCACCCAA 100 
101 CAGGCAAATC TGCCCMi;CGG GTACTACAAG TAGCTGTACA TCAAAGGCTG 150 
CC 
151 T AACATTGAG CTCCTTGATT CCTGAAGCAG AAGATAGCTG GTGGACGGGG 200 
201 ATTCTGCTA GTCTCGACAC GGCAGGCATC AAACTCACAG TTCCAATCGA 250 
251 GAAGTTCCCC GTGACAACGC AGACGTTTGT GGTCGGTTGC ATCAAGGGAG 300 
301 ACGACGCACA GAGTTGTATG GTCACGGTGA CAGTACAAGC CAGAGCCTCA 350 
351 TCGGTCGTCA ATAATGTCGC AAGGTGCTCC TACGGTGCAG ACAGCACTCT 400 
401 TGGTCCTGTC AAGTTGTCTG CGGAAGGACC CACT ACAA TG ACCCTCGTGT 450 
451 GCGGGAAAGA TGGGAGTCAAA GTTCCTCAAG ACAACAATCA GT ACTGTTCC 500 
501 GGGACGACGC TGACTGGTTG CA 
DS39 (opp sense) 
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6.2 BACTERIAL AND MOLECULAR METHODS 
6.2.1 Frequently used Solutions 
see section 2.2.1. 
6.2.2 Bacterial Growth Media 
Bacterial growth media components were added to 1 litre final volume. 
L-broth: 10 g Difco Bacto tryptone, 5 g Difco yeast extract, 5 g NaCI . 
L-agar: As above plus 15 g Difco agar. 
TYP broth: 16 g Difco Bacto tryptone, 16 g Difco yeast extract, 5 g NaCl, 12.5g 
~HP04· 
Ampicillin: Media was supplemented with 50 Ilg ml-1 ampicillin (Amp) when 
required. 
Tetracycline: Media was supplemented with 15 Ilg ml-1 tetracycline (Tet) when 
required. 
6.2.3 Growth and Maintenance of Bacterial Cells 
109 
Escherichia coli strains were grown on L-agar or in L-broth overnight (Maniatis et al. 
1982). Colonies on solid agar were maintained at 4°C, or alternatively long term storage 
was carried out at -70°C in L-broth containing 15% glycerol. Strains used in this study 
are described in Table 6.1. 
6.2.4 Preparation of Competent E. coli Cells 
Competent cells were prepared using the method of Chung et al. (1989). An overnight 
culture of E. coli was diluted 1: 50 in L-broth to the early exponential growth phase in a 
large flask with vigorous shaking until OD600 reached 0.3-0.4. The cells were then 
harvested by centrifugation at 2 000 g for 10 minutes at 4°C and the resulting pellet was 
resuspended in 0.1 volume of transport and storage solution (TSS) (L-broth containing 
10% (w/v) polyethylene glycol (pEG) 8 000, 5% (v/v) dimethyl sulfoxide (DMSO) and 
25 mM MgC12 pH 6.5). Cells were then stored at -70°C for 2-3 months. 
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Table 6.1 Escherichia coli strains. 
Strain 
JMI09 
BMH -18 mut S 
Genotype 
endAl, recAI, gyrA96, thi, hsdRl7 
(rk-, mk"1, relAI, supE44, Ll-, Ll 
(lac-proAB), [Ft, traD36, proNB+, 
laclq ZLlMI5] 
thi,supE,Ll(lac-proAB),[mutS::TnIO] 
[Ft, proA+B+, laclqZLlMl5] 
110 
Reference 
Yannish-Perron et al. (1985) 
Kramer, Kramer and Fritz 
(1984) 
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6.2.5 Restriction Endonuclease Digestion 
Restriction enzymes (Boehringer Mannheim) were used according to the manufacturer's 
instructions. Reactions were carried out using endonucleases at 10 units Ilg.1 with the 
appropriate 10X buffer supplied, and at the appropriate temperature for 2 hours. RNase 
was added at a final concentration of20 Ilg ml-1 when necessary. 
6.2.6 Dephosphorylation of Vector DNA 
Calf intestinal alkaline phosphatase (CIP) (Boehringer Mannheim) was used to remove 
5'-phosphate groups from linearised vector. Reactions were carried out in 10-20 III 
volumes by the addition of lOX CIP buffer (0.5 M Tris -HCl pH 9.0, 10 mM MgCI2, 
1mM ZnCI2, 10 mM spermidine) and 0.01 units ofCIP per)lg of DNA used. The volume 
was adjusted by the addition of sterile distilled water. Incubation was carried out at 37°C 
for 30 minutes followed by inactivation of CIP by heating at 75°C in the presence of 5 
mM EDTA. DNA was extracted with phenol/chloroform, followed by chloroform, and 
then precipitated by the addition of 0.1 volume 3 M sodium acetate and 2 volumes of 
ethanol. 
6.2.7 Phosphorylation of Primers 
When necessary, primers were phosphorylated at the 5' end. The reaction consisted of 
100 pmol primer, 2.5 III 10X kinase buffer (500 mM Tris-HCl pH7.5, 100 mM MgCI2, 
50 mM dithiothreitol (DTT), 1 mM spermidine, 10 mM ATP) and 5 units T4 
polynucleotide kinase, made up to 25 III with sterile distilled water. Incubation was 
carried out at 37°C for 30 minutes, followed by heating to 70°C to inactivate the kinase. 
Phosphorylated primers were stored at -20°C. 
6.2.8 Ligation Reactions 
Ligation reactions were carried out using insert and vector DNA at a ratio of 1:4. 
Ligation buffer (10X) (600 mM Tris-HC1, 50 mM Mg C12, 10 mM DTT, 10 mM ATP, 
pH 7.5) and T4 ligase were supplied by Boehringer Mannheim. Reactions were carried 
out using between 1 and 3 units of T4 ligase in 20 III volumes, made up with sterile 
distilled water. Incubation was at room temperature for 1-4 hours, or at 16°C overnight. 
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6.2.9 Transformation of Competent E. coli 
Transformation of competent E. coli cells was carried out using the method of Chung et 
al. (1989). Ligated plasmid DNA (25-50 ng) was added to 200 III competent cells and 
incubated on ice for 30 minutes. After heat shock at 37°C for 2 minutes, 0.8 ml of 
pre-warmed TSS was added, followed by incubation at 37°C for 1 hour with vigorous 
shaking. The cells were collected by centrifugation, and approximately 800 III of 
supernatant was removed before the pellet was resuspended in the remaining 200 Ill. 
Recombinants were selected by plating 50 and 100 III aliquots on L-agar plates 
containing an appropriate antibiotic (see 6.2.2) and 24 Ilg ml·1 isopropyl-D-
thiogalactopyranosidase (IPTG) (Bio-Rad), and 20 Ilg ml-1 X-galactose (X-gal) 
(Bio-Rad). After overnight incubation, recombinants appeared as white colonies against 
a blue background. 
6.2.10 Small Scale Preparation of Plasmid DNA 
Colonies were selected and inoculated into 10 ml L-broth and incubated overnight at 
37°C. Cells from 1.5 ml of culture were collected by centrifugation at 9 000 g for 30 
seconds, and were then resuspended in 100 III TEG (25 mM Tris-HCI pH8.0, 10 mM 
EDTA, 50 mM glucose). A 200 III volume of freshly prepared 1% (w/v) SDS and 0.2 
M NaOH was added and the contents of the tube were mixed by inversion, then 
incubated on ice for 5 minutes. This was followed by centrifugation at 9 000 g for 5 
minutes and removal of the supernatant containing the plasmid DNA. DNA was 
extracted using phenol/chloroform and then precipitated by the addition of 1 ml ethanol. 
The final pellet was resuspended in 50 III sterile distilled water. 
6.2.11 Large Scale Production of Plasmid DNA 
This was carried out using "Magic Megapreps DNA purification system" (promega). 
Cells from 600 ml of overnight culture were collected by centrifugation at 14 000 g for 
20 minutes. The pellet was resuspended in "cell resuspension solution" (50 mM Tris-HCI 
pH7.5, 10 mM EDTA, 100 Ilg ml-1 RNase A) and then lysed by the addition of 30 ml 
"cell lysis solution" (0.2 M NaOH, 1% SDS). The cell suspension was neutralized with 
30 ml 2.55 M potassium acetate (pH 4.8) followed by centrifugation at 14 000 g for 15 
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minutes. After transfer to a new bottle, a 0.6 volume of isopropanol was added to the 
supernatant. DNA was collected by centrifugation at 14 000 g for IS minutes and then 
re suspended in S ml TE. Plasmid was purified by the addition of 20 ml "DNA 
purification resin" and passing through a "Megacolumn" using a vacuum manifold. The 
resin was washed with (200 mM NaCl, 20 mM Tris-HCI pH 7.S, S mM EDTA), diluted 
1: 1 with 9S% ethanol, and then rinsed using 80% ethanol. DNA was eluted from the 
column by the addition of 3 ml sterile distilled water at 6S0C followed by centrifugation 
at 1 300 g for S minutes. 
6.2.12 Quantification of DNA 
See 2.2.8. 
6.2.13 Recovery of DNA from Agarose Gels 
DNA fragments were recovered from agarose gels using methods involving the use of 
powdered glass as described by Vogelstein and Gillespie (1979). 
Fragments Greater than 300 bp 
The "Gene clean 2" kit (Bio 101) was used to recover DNA fragments larger than 300 
bp from agarose gels. DNA present in agarose was excised from the gel and dissolved in 
2-3 volumes of3 M NaI at SO-SsoC. A S/ll volume of silica matrix in water ("glassmilk") 
was then added and the mixture was vortexed then left at room temperature for S 
minutes. The DNA-"glassmilk" matrix was centrifuged at 9 000 g for S seconds and 
washed three times with "NEW wash" (a solution of NaCI, Tris, EDTA and ethanol). 
DNA was then eluted in S /ll sterile distilled water at SO°C for 3 minutes, and the 
"glassmilk" removed by centrifugation at 9 000 g for 30 seconds. 
Fragments Smaller than 300 bp 
Small fragments of DNA were recovered from agarose gels using the "Mermaid" kit (Bio 
101) following manufacturer's instructions. The desired DNA band was cut from the gel 
and added to 3 volumes of "high salt binding solution". After the addition of 8 /ll 
"glassfog" (a silica matrix) per /lg DNA, the tube was vortexed for 10 minutes followed 
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by centrifugation at 9 000 g for 5 seconds. The supernatant was removed and the pellet 
washed with 300 III "ethanol wash". After centrifugation and two further washes, the 
DNA was eluted from the "glassfog" by resuspending the pellet in 10 III sterile distilled 
water, and then incubating at 55°C for 5 minutes. This was followed by centrifugation at 
9 000 g for 1 minute, after which the supernatant was transferred to another tube. 
6.2.14 Di-deoxy Chain Termination Sequencing 
DNA sequencing was carried out using the method of Sanger et al. (1977). All reagents 
were supplied in the T7 sequencing kit (pharmacia), except [35S]dATP (Amersham). 
DNA template (2 Ilg) was denatured by the addition of 0.4 M NaOH and incubating at 
room temperature for 10 minutes. This was followed by the addition of 0.3 volume of 3 
M sodium acetate (pH 4.8), 0.7 volume of distilled water and 6 volumes of ethanol to 
precipitate DNA. After centrifugation at 9 000 g for 10 minutes, the pellet was washed 
with 70% ethanol and then air dried and redissolved in 10 III distilled water 
Annealing reactions were carried out by the addition of 2 III of "annealing buffer" 
(solution containing MgCl2 and DTT) and 2 III of primer (final concentration 0.8 /lM) to 
10 III (2 Ilg) denatured template and incubating at 37°C for 20 minutes. 
T7 polymerase was diluted in "enzyme dilution buffer" (containing glycerol, BSA and 
DTT) to result in 3 units in 2 III for each reaction. An enzyme premix was made by 
adding the diluted enzyme to 1 III (10 IlCi) of[35S]dATP, 3 III "labelling mix A" (dCTP, 
dGTP and dTTP). Labelling reactions were then carried out by adding the premix to the 
annealed template and primer, and incubating at room temperature for 5 minutes to allow 
incorporation of [35S]dATP. The reactions were terminated by the addition of 4.5 III 
pre-warmed 'A', 'C', 'G' and 'T' mixes, which contained deoxy and di-deoxy forms 
(d/ddNTP's) of the respective bases. After incubation at 37°C for 5 minutes, 5 III "stop 
solution" was added and samples were stored at -20°C. 
Samples were then resolved using 6% PAGE which was prepared using 40% acrylamide 
stock (38% (w/v) acrylamide, 2% (w/v) bis-acrylamide), urea at a final concentration of 
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7 M, and 10X TBE (1 M Tris-HCI, 0.86 M boric acid, 20 mM EDTA). Prior to pouring 
the gel, 0.1% (w/v) APS and 0.05% (v/v) TEMED were added. Electrophoresis was 
carried out using 1 X TBE and S2 (BRL) apparatus at 50 watts constant power. Gels 
were pre-run for 30 minutes before adding 3.5 fll sample, which was freshly denatured at 
80°C for 2 minutes. Further samples were added 2 hours later, and electrophoresis 
continued for a further 3-4 hours. Gels were fixed using 10% (v/v) methanol, 10% (v/v) 
ethanoic acid and then transferred onto Whatman 3MM filter paper and dried under 
vacuum at 80°C for 30 minutes. 
Dried gels were exposed to X-ray film (Fuji) in radiography cassettes to detect 
[
35S]-labelled products. Film was developed in "Photosol" CDL8 developer and fixed in 
"Photosol" CF40 fix (Amersham). 
6.2.15 DNA Sequencing using the fmol System 
The "finol sequencing system" (promega) utilizes PCR technology in di-deoxy 
termination reactions. Extension / termination reactions were carried out by mixing 100 
ng template DNA, 0.8 flM primer, [35S]dATP (10 flCi fll-I) and "sequencing buffer" with 
the addition of sterile distilled water to a final volume of 16 fll. Sequencing grade Taq 
DNA polymerase (5 units) was then added. A 4 fll volume of this mixture was added to 
each of four tubes containing 2 fll d/ddNTP's ('A', 'C', 'G' and 'T'). After mixing, the 
reactions were overlayed with 20 fll mineral oil and placed in a thermal cycler (Hybaid) 
at 95°C. Thirty cycles were carried out (denaturation at 95°C for 30 seconds, annealing 
at 60°C for 30 seconds, and extension at 70°C). Reactions were stopped by the addition 
of "stop solution" and were then processed using PAGE as described in 6.2.13. 
6.3 ATTEMPTED MUTAGENESIS USING THE ALTERED SITES SYSTEM 
The "Altered Sites in vitro Mutagenesis System" (Promega) was used in an attempt to 
introduce two base pair changes necessary to create a novel restriction endonuclease site. 
This system consists of a mutagenesis vector (pAL TER-1) which contains two genes for 
antibiotic resistance, and a procedure for selection of oligonucleotide-directed mutants. 
The Tet gene is always functional, whereas the Amp gene is inactivated. After cloning 
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into pALTER, "helper phage" is used to make the plasmid single stranded. A primer 
provided with the kit, which restores Amp resistance is annealed to the single stranded 
DNA (ssDNA) along with the mutagenic primer complementary to the site, which 
contains the two base changes. Subsequent synthesis and ligation of the mutant strand 
links the two primers, and the DNA may then be used to transform BMH 71 cells. A 
second round of transformation in JM109 can then be carried out to separate mutant 
plasmids. 
6.3.1 The pALTER-l Vector 
The pALTER-1 vector is a phagemid containing the origin of replication from a single 
stranded DNA (ssDNA) bacteriophage (see Figure 6.2). The multiple cloning site (MCS) 
is flanked by SP6 and T7 RNA polymerase promoters and is inserted in the lac-Z open 
reading frame (ORF) which encodes B-galactosidase. The MCS allows cloning in a 
variety of sites using different restriction endonucleases which disrupts the lac-Z reading 
frame and so B-galactosidase is not produced. The presence of recombinant colonies can 
then be detected by growing the cells on an agar plate containing X-gal, which cannot be 
utilized and so these colonies appear white against a background of blue colonies. 
6.3.2 Cloning into the pALTER-l Vector 
P30 PCR product (522 bp) was recovered from an agarose gel using "Gene clean 2" and 
was then used in a ligation reaction with pALTER which had been digested with Sma I. 
This enzyme digests DNA to produce blunt ends and so was chosen because the PCR 
products should theoretically be blunt ended, therefore ligation should be possible. The 
ligated plasmid was transformed into competent JM109 cells, and incubated on L-agar 
containing X-gal, IPTG and Tet. This did not result in any recombinant colonies, and so 
the TA PCR vector (Invitrogen) was used in an attempt to clone the P30 fragment. This 
vector which contains an overhanging 'T' is recommended for cloning PCR products, 
which often contain an extra 'A' at the end of the fragment. Once cloned, the vector may 
be digested with EcoR I and then sub-cloned into pALTER for further investigation. 
However, transformation was again unsuccessful, with no recombinants growing on 
L-agar with L-Amp. 
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Figure 6.2 pALTER-l vector 
Sca I 4299 
T7l 
EcoRI 
pALTER-l Sacl 
KpnI 
on vector Sma I (5680bp) BamHI 
Xbal 
Sail 
Pst I 
SphI 
Hind III 
t SP6 
Figure 6.3 Primers used to clone P30 peR products 
DS38+ 
DS39+ 
AT A GAA TTC CGA CAG CCG CGG TCA TTC TC 
CCT GeT GeG ACT GAC CAA CGC TTA AGT TT 
Bold regions show EcoR I sites. 
117 
I start 
5 
15 
21 
23 
26 
32 
38 
48 
54 
56 
69 
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New primers (DS38+ and DS39+) which included EcoR I ends (see Figure 6.3) were 
then used in PCR reactions with original P30 product. The resulting PCR products (540 
bp) and pALTER were digested with EcoR 1 and then ligated. Transformation into 
JMI09 cells produced 20 recombinants, and small scale plasmid preparations followed by 
EcoR I digestion obtained a product of 532 bp. 
Digestion of the recombinant plasmid was carried out using Sac I to find the orientation 
of the fragment. There is one Sac I site in the MCS, and one in the PCR fragment 165 bp 
into the 522 bp fragment. Two fragments of 5680 bp and 357 bp were produced (see 
Figure 6.4). The orientation of the fragment is shown in Figure 6.5. 
6.3.3 Preparation of Phagemid ssDNA 
An overnight culture was used to inoculate TYP broth containing 15 Ilg ml- I Tet. This 
was incubated at 37°C for 30 minutes with vigorous shaking before infection with 10 
helper phage particles per cell ("helper" phage R408), and further incubation at 37°C 
overnight. Cells were separated by centrifugation at 12 000 g for 15 minutes, and helper 
phage was precipitated from the supematant by the addition of 0.25 volume 3.75 
ammonium acetate (pH 7.5) and 20% PEG 8000 on ice. After centrifugation at 12000 g 
for 15 minutes, the pellet containing phagemid DNA was resuspended in 400 III TE. An 
equal volume of chloroform was added to lyse the phagemid DNA. After centrifugation 
at 12 000 g to remove excess PEG, DNA was extracted from the supematant using 
phenol/chloroform followed by ethanol precipitation at -20°C. DNA was collected by 
centrifugation at 12 000 g and the pellet was washed with 70% ethanol, air dried and 
resuspended in 20 III sterile distilled water. Single stranded DNA was run on 0.8% 
agarose to reveal a band at 1.5 Kb (data not shown). The expected running point of the 
DNA was 6.2 Kb, however ssDNA often runs much lower than dsDNA, making size 
estimation difficult. 
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Figure 6.4 Sac I digestion of pALTER plus P30 fragment 
I 5680 bp 
522 bp 
357 bp 
1 2 3 
Lane 1: EcoR I digest of the recombinant plasmid 
Lane 2: Sac I digest of the recombinant plasmid 
Lane 3: DNA ladder (Cambio) 
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KB 
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Figure 6.S Orientation of the cloned P30 fragment. 
P30 
~T_7~ __ ~ ___ 1_65 __ -+ ______ 3_5_7 ____ ~ __ ~1 SP6 I 
EcoRI Sac I EcoRI 
Figure 6.6 The mutagenic primers. 
a) PI AGG CAA ATC TGC CCC CCG GGT ACT ACA AGT 
b) P2 ACT TGT AGT ACC CGG GGG GCA GAT TTG CCT 
~-------------------------------------------------------------------------~ 
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6.3.4 Mutagenesis Procedure 
Mutagenesis involved the annealing of the Amp repair oligo-nucleotide described earlier 
(see 6.3), and the mutagenic primer to the ssDNA template. The mutant strand was then 
synthesised using T4 DNA polymerase. The reaction consisted of 0.05 pmol recombinant 
pALTER ssDNA, 0.25 pmol Amp repair oligonucleotide (phosphorylated), 1.25 pmol 
mutagenic primer (phosphorylated) (Figure 6.6a), 2 III 10X annealing buffer (200 mM 
Tris-HCI pH7.5, 100 mM MgCI2, 500 mM NaCl) and distilled water to a volume of 20 
Ill. After heating at 70°C for 5 minutes, the reaction was cooled slowly to room 
temperature to allow annealing. This was followed by adding (on ice) 3 III "synthesis 
lOX buffer" (100 mM Tris-HCI pH7.5, 5 mM dNTP's, 10 mM ATP, 20 mM DTT), 1 III 
(10 units) T4 DNA polymerase, 1 III (2 units) T4 DNA ligase and 5 III sterile distilled 
water. Incubation was carried out at 37°C for 90 minutes to allow mutant strand 
synthesis and ligation. 
The DNA was then used in a transformation with BMH71-18 mut S (see Table 6.1). 
Mutants were selected by overnight culture in the presence of Amp. 
6.3.5 Results using the pALTER System 
Many white, and several blue colonies were present after overnight selection. Small 
scale plasmid preparations and Sma I digestion was carried out on twenty white colonies. 
Reaction products were then analysed by gel electrophoresis which revealed that they all 
contained the P30 insert, but none contained the Sma I site. The pALTER system was 
repeated, but was again unsuccessful in creating the mutated site. 
6.4 MUTAGENISIS USING PCR TECHNIQUES 
A method based on that of Higuchi et al. (1988) and Vallette et al. (1989) was used 
instead of bacterial cloning methods to produce a DNA fragment containing a mutation 
site. The system uses primer directed mutagenesis to produce a deletion, insert or 
substitution at any point of the fragment. By using the mismatched primer used in 6.6a 
(p 1), and another containing the same changes at the same site on the opposite strand 
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(P2), a Sma I restriction site may be introduced (see Figure 6.6b). This method is shown 
in Figure 6.7. 
6.4.1 Reactions Using Mismatched Primers 
Primers PI and P2 were used in separate reactions with primers DS39 and DS38 
respectively. Thirty cycles were carried out using P30 PCR reaction conditions, with the 
exception of the annealing temperature which was reduced to 50°C. This produced 
fragments of 131 bp (DS38 and P2) and 421 bp (DS39 and PI) (Figure 6.8). 
6.4.2 Combination of the PCR Products 
PCR products were run on 1 % agarose and the fragments were recovered by 
"Geneclean" and "Mermaid". DNA from both these fragments was denatured and 
renatured and then added to one PCR reaction using external primers only (DS38 and 
DS39) which produced a 522 bp fragment. Fragments of 118 bp and 404 bp were 
obtained respectively when these products were digested with Sma I (Figure 6.9). 
6.4.3 Cloning the Mutated Fragment 
Although qPCR could be carried out using the mutated fragment as a control in samples, 
it would be advantagous to consider the effects of other DNA from the host present in 
the system. Mutated P30 DNA was cloned into a vector for further manipulation. PCR 
was repeated using DS38+ and DS39+ with the mutated 522 bp fragment to introduce 
EcoR I sites for cloning into pBS SK+, and this was used to transform JMI09 cells. 
Cloned fragment could be used to create any amount of mutated template needed for the 
qPCR. 
6.4.4 Sequence Analysis 
T7 sequence analysis (pharmacia) (6.2.14) was unsuccessful in the analysis of the 
mutated DNA product. However the finol (Promega) (6.2.15) system revealed base 
changes of 'A' to 'C' and 'G' to 'C' at bases 116 and 117 bases respectively. This 
confirmed that in-situ PCR mutagenesis was successful. 
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Figure 6.7 Mutagenesis using the polymerase chain reaction. 
target sequence 
"left" peR with primer 
mutagenesis 
---------------~ ---------------~ 
"right" peR with 
primer mutagenesis 
----"------------------~----------------
Remove primers and 
DenatureiRenature 
5' ~--------­--------------~ 5' 
+ 
3' ~~----------------­-----------~ 3' 
+ 3' extension 
-- - - - -~------------------------------------~-- - - --
+ peR with outside primers 
__________________ -J~, __________________ _ 
--------------------'~,-------------------
(Adapted from Higuchi et al. 1988) 
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Figure 6.8 The peR using mismatched primers 
522 bp 
421 bp 
131 bp 
Lane 1: DS39 + PI 
Lane 2: DS38 + P2 
Lane 3: DS38 + DS39 
1 
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___ J 
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Figure 6.9 Sma I digestion of the peR products using mismatched primers 
522 bp 
404 bp 
11 8 bp 
Lane 1: DS38 + DS39 
3 KB 
\ 
Lane 2: DS38 + DS39 (using the products from the mismatched PCR) 
Lane 3: Sma I digest of products in Lane 2 
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CHAPTER 6 126 
6.5 QUANTITATIVE PCR 
Control reactions were carried out to investigate the accuracy of qPCR using the 
mutated P30 fragment in a competitive reaction. A series of titrations was carried out 
using two amounts of T. gondii DNA (1 pg and 10 pg) with varying amounts of mutated 
DNA in pBS SK+ (1 pg, 0.5 pg, 0.1 pg, 10 fg, 1 fg, 0.5 fg, 0.2 fg, 0.1 fg). Forty cycles 
were carried out under normal P30 PCR conditions (2.2.10). 
There is approximately one copy of P30 fragment in 0.07 pg of T. gondii DNA (7x107 
bp). However there are 2x104 copies in the same amount of vector plus mutated DNA 
(3.5x103 bp). As 1 pg of T. gondii DNA was added to the reactions, this equalled 
approximately 14 P30 copies or parasites. An equivelent number of copies of mutated 
P30 in pBS SK+ would be present in 0.49 fg. Equilibrium was reached between lanes 6 
and 7 (Figure 6.10) which contained 0.5 fg and 0.2 fg of mutated fragment respectively. 
When 10 pg of T. gondii was used in a qPCR, band intensity was roughly equal when 
between 2 and 5 fg of mutated fragment plus vector was added to the reaction (data not 
shown). The results were visible by eye and the results were relatively simple to interpret, 
however the smaller 118 bp fragment must also be considered and so densitometry was 
also applied to the gel (Figure 6.11). In the qPCR using 1 pg of Toxoplasma DNA this 
revealed that the point at which the levels of DNA were equal did lie between 0.5 fg (the 
digested bands were aproximately twice as intense), and 0.2 fg (the digested bands were 
aproximately one third as intense) ie. between lanes six and seven. 
6.5.1 Quantitative PCR with Patient Samples 
PM tissue samples which were previously recorded as PCR positive by either Bl or P30 
PCR (4.3.2) were analysed using qPCR. A total of26 tissue samples from seven patients 
which had been treated earlier (see 4.2.3) and stored at -70°C were tested. As before, 5 
,.d ofa 50 III preparation from 0.2 g of tissue was added to each PCR along with known 
dilutions of mutated DNA (2 pg, 0.5 pg, 0.1 pg, 10 fg, 5 fg, 1 fg, 0.1 fg). 
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Figure 6.10 Quantitative peR products after Sma I digestion to reveal true products (522 bp) 
and mutated DNA products (404 bp and 118 bp) 
522 bp 
404 bp 
118 bp 
1 2 3 4 5 6 7 8 KB 
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Figure 6.11 Densitometry of the qPCR products (lanes 6 and 7) from gel (Figure 6.10) 
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Toxoplasma DNA was quantified in 26 samples of DNA from these patients. However, 
only one set of titrations of mutated DNA from 2 pg to 0.1 fg was used due to the 
limited amounts of prepared samples available. Testing using the qPCR followed by Sma 
I digestion and gel electrophoresis enabled crude quantification of DNA from 56 000 
to 2.8 P30 copies in one tenth ofa 0.2 g tissue preparation. 
Tissue samples from three patients who died from active toxoplasmosis (one from group 
3 and another two who died before the study commenced) contained 100 to 500 times as 
many copies of the P30 fragment than those who were IgG positive with no clinical 
symptoms at death (see Table 6.2). Samples from the CNS and myocardium generally 
contained a higher number of parasites in comparison to other tissue types. 
6.5 DISCUSSION 
The lack of success using the pALTER Mutagenesis System was probably due to the 
failure of helper phage to successfully make ssDNA. The presence of dsDNA in the 
reaction would cause problems with primer annealing to the template. However, the 
Amp resistance oligonucleotide did result in the production of many Amp (mainly white), 
resistant colonies. Therefore there may also have been a problem with the mutagenic 
primer which meant that it was not incorporated in the synthesis of DNA. 
PCR technology was successful in producing a novel restriction site in the P30 gene. The 
P30 qPCR system was shown to be accurate in the assessment of parasite DNA in tests 
involving known amounts of T. gondii DNA (6.4.4). 
Quantification of DNA in human samples was possible, but only at crude levels due to 
the lack of prepared sample volumes. If larger sample volumes had been prepared, it 
would have been possible to carry out finer titrations close to the level detected by an 
initial series of reactions, and so therefore obtain a more accurate assessment of parasite 
numbers. The need for large volumes of prepared sample for full assessment would not 
normally be problematic in tissue testing. However samples such as blood and CSF may 
be in insufficient quantity to allow accurate quantification of parasite DNA. 
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Table 6.2 The quantitative PCR using human tissue samples. 
Patient Sample B1PCR P30 qPCR (Copies in Status at Death 
PCR 1110 of 0.2 g tissue) 
I Brain + + 1420 Clinical 
Thymus + - 142 toxoplasmosis 
2 Spinal Cord + - < 2.8 IgG+ 
3 Brain - + 28 IgG+ 
Spinal Cord 
-
+ 14 
Lymph Node - + 2.8 
Thymus - + 2.8 
Myocardium - + 142 
4 Myocardium + + 2850 Clinical 
toxoplasmosis 
5 Brain + + 285 Clinical 
Spinal Cord + + 142 toxoplasmosis 
Thymus + + 285 
Lymph Node + + 285 
Myocardium + + 285 
Bone Marrow + + 285 
Adrenal + - <2.8 
Spleen + - <2.8 
Pancreas + - <2.8 
Lung + - <2.8 
Liver + - <2.8 
Rectal Muscle + + 142 
Colon + - <2.8 
6 Brain + - <2.8 IgG+ 
Spinal Cord + - <2.8 
7 Brain + - 28 IgG+ 
Spinal Cord + - 142 
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Large amounts of DNA were located in the CNS and myocardium of patients, which is 
compatible with the areas problematic in T. gondii recrudescence due to AIDS and 
transplant therapy (Luft et al. 1983a, Speirs et al. 1988, Grant et al. 1990, Luft and 
Hather 1990, Dannemann et al. 1991). The detection of DNA in tissues of Toxoplasma 
IgG positive individuals with no signs of infection was probably due to the existence of 
tissue cysts. Increased levels of parasite in tissue may signify active infection rather than 
bradyzoites in tissue cysts. This may be of value as a research tool, but is of limited value 
in diagnosis, especially if invasive techniques such as biopsy are to be used. The system 
may be of greater value in examination of blood samples, where parasite is not usually 
detected except in cases of acute infection (van de Yen et al. 1991, Dupouy-Camet et al. 
1993). It would be interesting to test samples such as blood and urine from T. gondii IgG 
positive individuals who were PCR positive but who do not appear to have clinical illness 
(4.3.2) using qPCR. This may reveal whether detected parasite was due to intermittent 
cyst breakdown (where DNA is detected at low levels), or to a mild parasitaemia which 
may be problematic in the future (where DNA is detected at higher levels). The qPCR 
would also be of value in following the effects of drug therapy using blood samples from 
patients. However serial blood sampling would be required using larger samples or 
preparations diluted in larger volumes of buffer (200 III compared to 50 Ill). This may in 
turn result in a dilution effect, where samples containing low levels of parasite are 
negative using the PCR. 
CHAPTER 7 
Discussion 
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7.1 INTRODUCTION 
The majority of methods currently used to diagnose T. gondii infection involve the 
detection of IgG and IgM in blood samples. Direct methods such as microscopy and 
culture are insensitive or time consuming and so are of little diagnostic value. In the 
1970's and 1980's work concentrated on the development of an antigen ELISA as a 
sensitive and efficient way of detecting the parasite directly. The need for a such a test 
became more obvious as the incidence of AIDS increased in the population, and 
serological testing failed to detect recrudescence of infection in these and other 
immunocompromised patients. Because of a lack of specific tests invasive procedures 
such as brain biopsy were often used to confirm the diagnosis following MRI and CAT 
scans. Previous studies revealed success rates varying from 5.7% (van Knapen and 
Panggabean 1977) to 63.6% (Araujo and Remington 1980) using the antigen ELISA. 
More recently the PCR has been used to detect a wide variety of pathogens from human 
and animal samples and initial work on the detection of T. gondii using this technique 
investigated the use of the P30 gene (Savva et al. 1990), and the B 1 gene (Burg et al. 
1989). Both PCR systems were shown to detect parasite in mock samples (Joss et al. 
1993, Savva et al. 1990), and also in limited clinical samples (Holliman et al. 1991a, 
1991b, Verhofstede et al. 1993). 
The primary aim of this study was to develop and assess a sensitive and specific system 
to detect T. gondii. This could then be used to diagnose toxoplasmosis In 
immunocompromised patients and follow the effects of drug therapy, as well as 
investigate the complex relationship between the parasite and the host. 
7.2 THE DETECTION OF T. GONDII 
In the present study both the antigen ELISA and the PCR were successful in detecting T. 
gondii, however the PCR was found to be approximately 500 times more sensitive than 
the ELISA. Other workers have developed the PCR to detect a wide variety of 
organisms in which conventional serological screening has been problematic, such as 
mv (Laure et al. 1988), Papillomavirus (Morris et al. 1988), CMV (Shibata et al. 1988, 
Gozlan et al. 1992) and Pneumocystis carinii (Wakefield et al. 1990). The technique has 
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greatly increased sensitivity in comparison to other tests and has been widely introduced 
in diagnostic and research laboratories. If chosen carefully, primers result in the 
amplification of specific products with great sensitivity, however consideration must be 
given to the specialised facilities and equipment required for this technique which may 
not be currently available in many laboratories. These technical problems may therefore 
limit its use as a diagnostic tool. 
Further work concentrating on the PCR included experiments under controlled 
conditions to investigate its use in a diagnostic setting, and to study parasite / host 
interaction. Both the Bland the P30 PCR were used successfully to detect DNA from 
between one and five parasites in a sample. However the B 1 system was found to be 
more sensitive, enabling the detection of DNA from one parasite by gel electrophoresis. 
This sensitivity is due to the repetitive nature of the B 1 gene, in comparison to P30 
which is a single copy gene (Verhofstede et al. 1993). Initial work suggested that this 
great sensitivity may cause contamination problems; an area of concern in the diagnostic 
setting. Precautions were therefore taken to avoid contamination which included the use 
of positive displacement pipettes, plugged tips, the use of gloves, and U. V. irradiation of 
equipment. The negative controls contained in every run ensured that false positive 
results were avoided, and it was demonstrated that PCR may be used in the routine 
diagnosis of T. gondii infection. 
Both the B1 and P30 PCR detected a "window" of parasitaemia in experimentally 
infected sheep (Chapter 3). Parasite was detected in samples oflymph and blood several 
days after infection and then for three to five days before disappearing. Therefore a 
primary infection involves a parasitaemia which may allow the parasite to invade and 
encyst in many tissues. When immunocompetent patients with primary toxoplasmosis 
were observed and followed, parasite was found to persist in the blood for a longer 
period than that observed in sheep. This was most likely due to the use of the incomplete 
strain (S48) of T. gondii used to inoculate sheep, compared to wild type infections in the 
patients. 
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Parasitaemia was found to be transient in immunocompromised patients suffering from 
recrudescence of a chronic infection, however parasite was detected in blood samples 
from patients up to one month prior to any clinical evidence of infection. The detection 
"window" lasted for only a short time, often for only a few days, indicating that sample 
timing was therefore critical in the detection of parasitaemia. This result also reveals that 
recrudescence is not completely due to localised reactivation of tissue cysts, but may be 
due to a more widespread parasitaemia as suggested by Luft and Remington (1992). 
T. gondii DNA was detected in the blood of several patients with no clinical evidence of 
infection. These patients had a slightly higher CD4+ cell count than those with clinical 
toxoplasmosis, therefore DNA may be detected from intermittent cyst breakdown or 
from the occasional breakdown and release oftachyzoites. This may still be controlled by 
the hosts limited immunological response, but could indicate that the patient is at risk in 
the future if their CD4+ cell count drops further, allowing a greater and more widespread 
parasitaemia. 
Parasite was not detected in blood samples from one patient with confirmed toxoplasma 
encephalitis, but tissue samples obtained at PM examination were found to contain T. 
gondii DNA using the PCR. There is therefore a question as to whether the parasitaemia 
was missed, or whether localised reactivation had occurred. Localised reactivation seems 
unlikely in this case because of the wide range of tissues involved. 
7.3 THE ANIMAL MODEL OF RECRUDESCENCE 
The mouse model of recrudescence of T. gondii infection was developed to clarify 
several points regarding parasite / host interaction. Firstly, only one third of patients with 
AIDS and chronic T. gondii infection suffer any clinical signs of recrudescence (Grant et 
al. 1990), therefore there is a need to identify those at risk. Secondly, the incidence of 
parasitaemia required further investigation into the level and timespan over which the 
parasite may be detected in relation to clinical evidence of toxoplasmosis. 
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Dexamethasone treatment resulted in increased mortality in chronically infected mice. 
However two other effects were also observed: an increase in the number of mice with 
evidence of parasitaemia, and an increase in pathological evidence of active infection. 
The rate of recrudescence was similar to that in the AIDS population with past exposure 
to the parasite, with both having a occurence of 30-35%. This similarity was not seen in 
previous models developed to investigate recrudescence where nearly all mice died as a 
result of immunosuppressive therapy (Lindberg and Frenkel 1977, 10hnson L 1992, 
Vollmer et al. 1987). In both the mouse and the human population not all individuals 
with T. gondii DNA in the blood showed clinical signs of illness. Examination of samples 
obtained at PM examination revealed a high number of brain samples from chronically 
infected animals to contain parasite, and an increase in the number of positive heart 
samples from sick animals. Blood samples were found to be of limited diagnostic value 
because of the number of samples in which DNA was detected, but with no clinical 
symptoms of toxoplasmosis within the timescale of the study. Therefore it would be 
worth pursuing this model over a longer time scale to see if animals with parasitaemia do 
eventually become ill. A similar effect, where parasite was detected in patients without 
clinical signs of infection was recorded by Hassl et al. (1988) using an antigen ELISA. 
They concluded that the presence of antigen was not indicative of an active infection, 
contradicting van Knapen and Panggabean (1977) and Araujo and Remington (1980) 
who recognised the importance of circulating parasite. This study highlights the presence 
of a parasitaemia prior to clinical evidence of recrudescence, however the detection of 
parasite in the blood did not necessarily mean that toxoplasma encephalitis would occur 
within the six week period of this experiment. 
7.4 QUANTITATIVE peR 
The qPCR was successfully used to assess the level of infection in human samples at PM 
examination. In these samples, levels of parasite were higher in those patients who had 
clinical evidence of toxoplasmosis, compared to those with a chronic infection. However 
it was not possible to differentiate between active and latent infection, and further 
investigation would be required to establish a cut-off point between the two stages of 
infection. 
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The cloned mutant DNA created for the qPCR would also be useful as a control in all 
samples tested using the PCR. It could be amplified with the sample directly and negate 
the need for testing samples containing a known amount of DNA in a second reaction to 
eliminate false negative results (Chapter 4). 
7.5 FUTURE WORK 
As well as investigating recrudescence in the immunocompromised host, the PCR could 
also be used to assess the risks of damage to the foetus when the mother contracts a 
primary T. gondii infection during pregnancy. An animal model, using mice for example, 
may reveal the level of damage associated with different levels of parasite in the amniotic 
fluid. Quantitative PCR will therefore be useful in such an investigation, with the ability 
to differentiate between low and high levels of parasite. 
Dexamethasone may also be of value in the investigation of other infections which affect 
the immunocompromised host. A similar model has been used successfully to study 
Pneumocystis carinii (Powles et al. 1992,) and the problems associated with CMV, 
Herpes simplex (Katz et al. 1990) and Mycobacteria (Saboor et al. 1992) in AIDS 
patients may be studied using this method. As these organisms result in chronic infection 
and can cause symptoms similar to those seen in toxoplasmosis in the CNS, it may be 
possible to improve diagnosis by using one sample to test for a range of these pathogens. 
The model may also be used to study genetic differences in the control of recrudescence 
by investigating different strains of mice (Suzuki et al. 1991, McLeod et al. 1989). This 
may in turn lead towards a method of investigating genetic differences in animals prone 
to recrudescence, and therefore highlight those at risk. 
The qPCR could be applied to the mouse model to find if only high levels of parasitaemia 
result in recrudescence, therefore revealing vulnerable individuals. This may then be 
extrapolated to patient samples, and be used to monitor the affects of therapy. 
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Although the qPCR detected different levels of parasite in various human tissues, it was 
not used to differentiate between active and latent infection in this study. It would be 
possible to further develop the system to produce a cut-off point above which the levels 
of DNA indicate active parasite, but a more accurate method of locating the active 
tachyzoite would be the amplification of RNA. This technique has been used by others to 
detect latent Herpes simplex (Katz et al. 1990) and mv (Arrigo et al. 1990, Pang et al. 
1990). However this would be complex to develop as the process would involve reverse 
transcription to make cDNA from the RNA present, followed by amplification (RT 
PCR). There would also be a risk that genomic DNA coding for the same product may 
be amplified (Gilliland et al. 1990). It would therefore be necessary to span introns and 
exons in the amplified region which would vary the size of amplification product, and so 
differentiate between any contaminating genomic DNA. The RNA from the P30 gene, 
which codes for the P30 surface protein only found in the tachyzoite, would be a suitable 
target but it does not contain any introns (Burg et al. 1988). The genes which do contain 
introns and which could be considered include the a and B tubulin, Bland P28 genes. 
In-situ PCR may provide information on the location of the parasite in different cell type, 
for example in tissue sections, or cytospins of blood cells. Currently in-situ hybridisation 
has been used to examine single cells for a range of organisms in wide variety of samples 
(Foley et al. 1993). This would distinguish between the presence of DNA in tissue cysts 
and tachyzoites and therefore indicate whether the parasite was active or latent. In-situ 
hybridisation can also be combined with RT qPCR (Foley et al. 1993) which may 
provide further information on the location and activity of the parasite. 
7.6 CONCLUDING REMARKS 
The PCR has been demonstrated to be a sensitive and specific method of detecting T. 
gondii DNA. It is potentially a valuable tool in the diagnosis of infection in patients 
where conventional testing is of limited value. This study shows the B 1 PCR to be the 
system of choice due to its superior sensitivity. However there were several problems 
associated with the system such as the risks of sampling error, and the detection of 
parasite in a small number of patients who were clinically well. Therefore the B 1 PCR 
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should be used in combination with other systems such as MRl and CAT scans, and the 
presence of other pathogens should be negated. There was no evidence of false positive 
results in either the patient or animal studies using this system, so any future positive 
results in a clinical setting must be taken seriously and patients should subsequently be 
closely monitored. Quantitative PCR may also reveal whether the DNA detected is at a 
level likely to result in illness, and would be an ideal way to monitor the progress of 
infection. It may also indicate whether therapy would successfully prevent recrudescence 
in patients who are at particular risk. 
The animal and patient studies revealed that parasitaemia was present in both primary 
infection and in recrudescence of a chronic infection. The duration of parasitaemia was 
considerably shorter in cases of recrudescence than in primary infection, but as it 
occurred well before clinical signs of illness, therapy may be considered prior to any 
clinical signs of encephalitis. Until more appropriate drugs are available which would 
specifically treat the tissue cyst, the presence of parasite at any level should warrant the 
initiation of conventional therapy alongside careful management of the patient. 
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APPENDIX I 
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Bio 101 Inc., PO Box 2284, LaJolla, CA., 92038 USA. 
Bio-Rad Laboratories Ltd., Bio-Rad House, Maylands Avenue, Hemel Hempstead, 
Hertfordshire, UK. HP2 7TD. 
Boehringer Mannheim, Bell Lane, Lewes, East Sussex UK. BN7 1LG. 
Cambio, 34 Millington Road, Cambridge, UK. CB3 9HP. 
Chernicon International Plc., (agents for Quadratech) 27515 Enterprise Circle West, 
Temecula, CA., 92590 USA. 
Gibco Life Technologies Ltd., PO Box 35, Trident House, Renfrew Road, Paisley, 
Strathclyde, UK. PA3 4EF. 
Invitrogen, Rand D Systems Europe Ltd., 4-10 The Quadrant, Barton Lane, Abingdon, 
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Nycomed, (Division Diagnostica) PO Box 4284, Torshov N-0401, Oslo 4, Norway. 
Oswell DNA Services, Department ofChernistry, University of Edinburgh, Kings 
Buildings, West Mains Road, Edinburgh, UK. EH93JJ. 
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